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Abstract 
In spite of remarkable improvements in cancer treatments and survivorship, cancer still 
remains as one of the major causes of death worldwide. Although current standards of care 
provide encouraging results, they still cause severe systemic toxicity and also fail in 
preventing recurrence of the disease. In order to address these issues, biomaterial-based 
implantable drug delivery systems (DDSs) have emerged as promising therapeutic platforms, 
which allow local administration of drugs directly to the tumor site. Owing to the unique 
properties of biopolymers, they have been used in a variety of ways to institute biodegradable 
implantable DDSs that exert precise spatiotemporal control over the release of therapeutic 
drug. Here, we review the most recent advances in biopolymer-based DDSs for suppressing 
tumor growth and preventing tumor recurrence. We discuss novel emerging biopolymers as 
well as cutting-edge polymeric micro-devices deployed as implantable anti-tumor DDSs. 
Lastly, a review of a new therapeutic modality within the field, which is based on implantable 
biopolymeric DDSs, is given.  
 
 
1. Introduction 
Cancer is a disease that arises from mutated cells that have acquired the capacity to proliferate 
indefinitely and evade apoptosis which eventually leads to tumor formation and subsequent 
invasion to surrounding tissues (also known as metastasis).
[1, 2]
 Accordingly, advanced cancer 
is viewed as a “systemic” disease that requires systemic treatment and on account of such 
notion systemic administration (administered by intravenous injections) of chemotherapeutic 
drugs has been established as one of the standard methods to treat cancer. 
[3-5] 
Traditional 
systemic chemotherapy has many limitations in treating the disease including: low efficiency 
of delivering the drugs specifically to the tumor site at therapeutic concentrations, and the 
ensuing toxicity to healthy tissues. 
[6-8]
 Consequently, local delivery systems have entered the 
fray to address the shortcomings of systemic delivery, by delivering the drug directly to the 
tumor site using an implantable system (Figure 1).
 [9, 10]
 The implantable drug delivery system 
(DDS) contains one or more therapeutic agents while being placed around or inside the tumor 
to facilitate targeted delivery.
[11, 12]
 These DDSs are intended to enhance drug uptake and 
efficacy since they (I) are delivered locally (directly at the site of the tumor) and therefore 
offer strategic and precise spatial control that significantly reduces the required drug dosage 
and often the side/off-target effects, (II) present temporal control over release profile of 
chemotherapeutic agents to maintain therapeutic concentrations over a longer duration of time 
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and (III) protect the loaded drugs from degradation or clearance until they are released.
[4, 6, 13, 
14] 
In the past decade, a wide variety of biomaterials have been exploited to institute anti-
cancer implantable DDSs, and the properties afforded by biopolymers (such as 
biocompatibility, biodegradability, and ease of processing), has led to recent increased 
attention.
[9, 15-17]
 A significant advantage of biopolymeric implantable DDSs is that they do 
not demand  surgical extraction after use, as they can be cleared naturally by the body.
[18]
   
Biopolymeric implantable DDSs are classified under two distinct categories, pre-formed 
systems or systems that are formed after the injection into the tumor site.
[19]
 Pre-formed 
implants have been made from commercially available and FDA (U.S. Food and Drug 
Administration) approved synthetic biopolymers such as polycaprolactone (PCL), polylactic 
acid (PLA) and poly(lactic-co-glycolic) (PLGA) - or naturally occurring polymers including 
alginate, gelatin, silk and dextran. Pre-formed systems were typically fabricated through well-
established fabrication methods such as casting, electrospinning and 3D printing.
[20-39]
 On the 
other hand, in-situ formed implants are realized by direct injection into the tumor site, 
typically using gels that solidify in response to either temperature or pH (Figure 1).
[40-55] 
Biopolymeric implantable DDSs have shown to be capable of releasing the therapeutic agents 
either actively (stimuli-responsive systems) or passively (non-stimuli responsive systems). 
Accordingly, stimuli-responsive systems showed a rapid change in dimension or physical 
properties, instigated by either internal stimuli within the body, such as temperature or pH, or 
external stimuli such as electromagnetic waves, ultrasound, visible-, infrared (IR)- and near 
infrared (NIR)-light (Figure 2).
[56-60]
 With non-stimuli responsive systems release is passive 
and controlled by diffusion, drug-carrier affinity, degradation of polymer, and/or any 
combination of these 
[13, 61, 62]
. Therefore, in these systems factors such as tortuosity of pores, 
steric interactions between drug and matrix, reversible chemical interaction of drug and 
matrix, and molecular weight of polymeric matrix determine the release profile of the 
therapeutic agent in question.
[13, 63]
 Overall, application of the biopolymeric implantable 
DDSs for cancer therapy goes beyond delivery of anti-neoplastic agents (e.g. 
chemotherapeutic drugs), as recently they have been successfully applied to other cancer 
therapeutic modalities (Figure 1) including hyperthermia; local heating of tumors to a very 
high temperature using electromagnetic waves or NIR radiation.,
[48]
 photo-dynamic therapy; 
utilization of photosensitizing agent and a particular type of light that produce reactive oxygen 
species to induce cancer cell death.,
[54]
 gene therapy; treating the disease using small 
interfering RNAs (siRNA) and microRNAs (miRNA).,
[64]
 and immunotherapy; aiding the 
immune system to eradicate the malignancy.
[65]
 Interestingly, these DDSs were also shown to 
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be capable of taking on a combination of multiple therapeutic modalities such as 
chemotherapeutic drugs and gene therapy, to synergistically treat malignant tumors.
[66, 67] 
Nonetheless, implantable biopolymeric DDSs have been commonly used in two different 
ways to aid in the treatment of various cancers; they can either be used as neoadjuvant or 
adjuvant therapies, in which the tumor itself can be treated (neoadjuvant) or the site where the 
tumor was removed can be treated to prevent cancer reoccurrence (adjuvant).
[19] 
 
In this paper, we will review the most recent progress in biopolymer-based DDSs for 
abrogating various tumors. We will specifically focus on studies with preclinical in vivo 
evidences or those with clinical evaluations, as we believe these studies are of higher value 
for transition of DDSs from concept to clinical application. We will further highlight various 
fabrication methods commonly deployed for making these DDSs and review the anti-tumor 
performance of some recent impressive examples. Additionally, we will evaluate future 
direction of anti-tumor implantable DDSs in regards to emerging biopolymers as well as 
cutting edge polymeric microdevices deployed as implantable anti-tumor DDSs. To conclude, 
a novel emerging therapeutic modality based on biopolymeric implantable DDSs for 
treatment of various cancers is highlighted. 
 
2. Implantable anti-tumor DDSs   
 
This section aims to give a brief overview of the most commonly used methods for 
construction of implantable DDSs and subsequently provide a comprehensive review of 
ensuing implantable DDSs for tumor abrogation (and prevention of tumor recurrence) in 
preclinical in vivo and clinical studies.    
  
2.1 Preformed Implants 
 
Owing to specific features of preformed implants, such as their structural integrity and 
defined geometric shapes, these implants endow predictable and adjustable long-term release 
and degradation profiles. In vivo implantation of these systems typically entails an invasive 
surgery.
[12, 15]
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2.1.1 Cast implants 
 
Casting is considered one of the oldest fabrication methods and it can be further divided into 
different subcategories such as solvent casting/particulate leaching, gel casting or melt casting. 
Regardless of the sub category it involves pouring the polymer solution/melt into a cast and 
subsequently solidifying the precursor through heat/chemical or physical cross-
linking/recrystallization.
[68-70]
 One of the main perks of casting is the flexibility in choice of 
material as it can be easily applied to thermoplastic biopolymers (such as PLA, PLGA or 
PCL) as well as natural/synthetic hydrogels. Moreover, it can be utilized for fabrication of 
either 2D films or 3D delivery systems.
 [20-22, 29, 71-73]
 However, casting comes up short in 
producing structures wherein porosity, mechanical properties and/or composition as well as 
the distribution of these is controllable. Nevertheless, on account of its simplicity it has been 
widely employed for fabrication of anti-cancer DDSs from various biopolymers. 
[22, 71, 74] 
 
Silk: 
Silk fibroin, a protein based material, has been gaining a foothold in biomaterials science and 
oncology therapeutics.
[75, 76]
 In addition to the use of silk materials for disease therapy for 
centuries, they are FDA approved for implantation as a bioresorbable scaffold.
[77]
 Moreover, 
biodegradable materials based on silk fibroin isolated from Bombyx mori silkworm cocoons 
have been shown to induce minimal immune response in vivo.
[78, 79]
 Consequently, it was 
observed that this type of protein can be combined with various anti-cancer drugs to bring 
about anti-tumor activity. For instance, recently, delivery of vincristine and doxorubicin 
(DOX) from silk foams, for treatment of neuroblastoma in a mouse model, has been 
investigated.
[24]
 These implants were fabricated by lyophilization of silk solution inside a 
mold and subsequent thermal cross-linking at 121 ºC. The silk implants were placed 
intratumorally and the in vivo results revealed that silk foams loaded with vincristine, with 
and without DOX, significantly decreased neuroblastoma tumor growth, increased tumor drug 
availability and decreased ultimate plasma concentration compared to intravenous (IV) drug 
treatment. In another study, silk films loaded with DOX were used to suppress primary tumor 
growth as well as metastasis in breast cancer mice model (Figure 3). 
[22]
 The in vitro results 
revealed a direct correlation between absorption of DOX on silk films and silk crystallinity 
(beta-sheet content) that enabled controlled release of drug. The in vivo findings ensuing 
implantation of films at the primary tumor site indicated that silk films loaded with DOX had 
greater primary tumor response when compared to equivalent dosage of drug administered 
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intravenously. In addition, drug loaded stabilized films showed reduction in metastatic 
dissemination as a result of locoregional control of the disease.   
 
Gelatin: 
Gelatin a natural protein derived from hydrolytic degradation of collagen, has attracted much 
attention in the biomedical field owing to its biocompatibility and biodegradation in 
physiological environments.
[80-82]
 However, gelatin has a sol-gel transition temperature around 
30 ºC, and so needs to be cross-linked to avoid dissolution at body temperature.
[83]
 Yet, in the 
context of cancer drug delivery this property can be leveraged to allow controlled release of 
the drug in a temperature-dependent manner. For example, Zhang et al., made a physically 
cross-linked gelatin hydrogel that was embedded with poly(ethylene glycol)-block-
poly(caprolactone) (PEG-b-PCL) nanoparticles ,which were co-loaded with tetrandrine (Tet) 
and paclitaxel (PTX), and evaluated the performance of this implant (P/T-NPs-Gelatin) for 
treatment of gastric cancer in mice model.
[20]
 These hydrogel implants underwent a gradual 
gel-sol phase transformation at 37 ºC, which resulted in controlled release of drug loaded 
nanoparticles. In vivo results showed that P/T-NPs-Gelatin implants had the greatest 
inhibitory growth effect when compared to either intraperitoneal delivered P/T-NPs or free 
combinations of PTX and Tet. Similarly, a gelatin hydrogel loaded with gelatin/poly(acrylic 
acid) nanoparticles containing cisplatin (CDDP) was used for treatment of liver cancer in a 
murine hepatoma cancer model.
[26]
 It was found that implantation of the gelatin hydrogel 
containing CDDP-loaded nanoparticles on tumor tissue led to a remarkably higher efficacy in 
preventing tumor growth as well as prolonged lifetime of the mice compared to that of IV 
injected CDDP-loaded nanoparticles. More importantly, bio-distribution results revealed that 
these gelatin hydrogel implants yielded a much higher drug concentration in tumor and far 
less accumulation in non-target organs when compared to that in the group which received 
systemic administered CDDP-loaded nanoparticles. Since gelatin has a variety of functional 
groups on its side chains, they can be exploited in various ways to crosslink the hydrogel 
either chemically or physically.
[83]
 Accordingly, Jaiswal et al., developed a hydrogel implant 
by in-situ polymerization and cross-linking of acrylic acid with polycaprolactone diacrylate in 
the presence of gelatin.
[25]
 It was shown that an increase in crosslinker concentration led to a 
slower degradation rate as well as drug release. Additionally, the semi-interpenetrating 
network of gelatin and poly-(acrylic acid) loaded with DOX was implemented as an adjuvant 
therapy by implanting it into the tumor cavity post tumor resection to prevent recurrence of 
breast tumors in mice models. It was observed that use of this drug-loaded implant led to 
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prevention of tumor recurrence after resection until day 25 as opposed to implants with no 
drugs which showed tumor relapse on day 18. 
 
Dextran: 
Dextran is a polysaccharide of microbial origin consists of glucose molecules connected via a 
1-6 glucosidic linkage while side chains are connected in a 1-4 linkage.
[84]
 Aside from its 
biocompatibility and biodegradability, this polymer is resistant to protein adsorption and 
consequently it was deployed as drug delivery vehicles.
[85]
 Owing to abundance of hydroxyl 
groups in this polymer, one can partially oxidize them to produce aldehyde groups that can be 
crosslinked by addition of amine-containing polymers.
[86]
 For instance, based on a schiff-base 
interaction between dextran-aldehyde and polyamidoamine (PAMAM) dendrimers, an 
implantable hydrogel was made, which was embedded with poly(β-aminoester) nanoparticles 
containing anti-luciferase siRNA.
[21] 
 This composite hydrogel was tested in vivo in a 
xenograft mouse model for human breast cancer, and showed no sign of inflammation after 
implantation. All mice subjected to these implants maintained healthy conditions indicating 
implant biocompatibility. Furthermore, nanoparticle loaded hydrogels promoted efficient 
luciferase silencing, with up to 70% reduction in luciferase expression after day 6, which was 
significant when compared to 20% reduction of luciferase expression achieved by 
intratumoral injection of nanoparticles after the same period of time. Conde et al., loaded the 
same hydrogel with dark-gold nanoparticles modified with 5-fluorouracil (5-FU)-intercalated 
nanobeacons, which acted as an on/off switch activated by the increase of multidrug 
resistance protein 1 (MPR1) within the tumor microenvironment.
[66]
 These nanoparticles were 
specifically designed to detect and target MPR1 genes, a process that triggered concomitant 5-
FU release following nanobeacon opening. Consequently, in vivo implantation of these 
nanoparticle loaded hydrogels resulted in over 90% tumor reduction in a triple-negative breast 
cancer (TNBC) mice model as a consequence of 80% MPR1 silencing.  
In other work by this group, the same hydrogels were simultaneously loaded with gold 
nanospheres decorated with siRNAs and gold nanorods containing the anti-cancer drug 
bevacizumab(Avastin®), to bring about a “combinatorial” triple-combination therapy for 
tumor regression as well as recurrence prevention in a colon cancer mice model (Figure 4).
[67]
 
The gold nanospheres were designed to specifically silent a major oncogene driver (Kras) in 
colorectal cancer (CRC) progression, while the gold nanorods had the capacity to convert NIR 
radiation into heat causing release of the drug as well as photothermal therapy to ablate 
tumors. Accordingly, this triple therapy hydrogel (gene therapy, chemotherapy and 
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phototherapy combination) synergistically abrogated the tumor, and following resection it 
completely prevented colon cancer recurrence. Furthermore, animals which received triple 
therapy have shown 100% survival for at least 170 days which was significantly higher 
compared to control groups that received monotherapies. Conde et al., also established a self-
assembled hydrogel containing RNA-triple-helix to modulate miRNA in the tumor 
microenvironment.
[64]
 This system was comprised of RNA-triple-helix conjugated in 
PAMAM G5 dendrimers (triplex nanoparticles) which formed the hydrogel upon mixing with 
dextran aldehyde. The RNA-triple-helix was formed by self-assembly of two miRNA 
oligonucleotides, an antagomiRNA used to inhibit an oncomiRNA and a miRNA mimic used 
as tumor suppressor. This nanoparticle loaded hydrogel were subsequently implanted in 
TNBC mouse models, which led to almost 90% tumor size reduction 13 days after hydrogel 
disk implantation, as well as a significant survival advantage in comparison to drug-loaded 
hydrogels. The highly selective and specific treatment of tumor cells has been shown to be the 
main advantage of this system over traditional chemotherapeutic drugs. 
 
PLA and PLGA: 
PLA is an US FDA approved synthetic biocompatible polymer, belonging to poly (α-hydroxy 
acid) class, which offers extensive mechanical properties and undergoes in vivo hydrolytic 
degradation through de-esterification.
[87] 
However, long degradation times along with high 
crystallinity causing fragmentation can result in inflammatory reactions in vivo.  Numerous 
methods have been used to decrease crystallinity and subsequently hasten biodegradation.
[88]
 
For instance, copolymerization of lactic acid and glycolic acid has produced PLGA with 
tunable degradation based on the ratio of lactic acid to glycolic acid.
[89, 90]
 Hence, on account 
of desirable properties of PLGA this copolymer was extensively used in variety of clinical 
applications including drug delivery systems for cancer therapy.
[91]
 For instance, Wang et al., 
incorporated nanoparticles of RGD-modified PEGlated PAMAM dendrimer loaded with 
DOX (RGD-PPCD) into PLGA/PLA solution containing PEG (polyethylene glycol; as drug 
release modifier) and then casted them into a cylindrical die.
[73]
 In vitro release studies 
revealed that the ratio of PLGA/PLA had an impact on the release of DOX, with an increase 
in PLA content decreasing the drug release rate. It was also observed that different amounts of 
PEG can influence the DOX release, as an increase in PEG led to significant increase in 
release rate of DOX. Furthermore, in vivo results indicated that PLG/PLA scaffolds 
containing RGD-PPCD nanoparticles could significantly reduce glioma tumor size in mice as 
opposed to their counterparts including PPCD implant, DOX implants and blank implants. 
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These findings were assumed to be result of better penetration of RGD-PPCD nanoparticles 
into the tumor which highlighted beneficial role of RGD sequence in tumor retention of 
nanoparticles. PLGA was also utilized to fabricate a biopolymeric cylindrical implant, known 
as local drug eluter (LODER), that contained an siG12D (an siRNA against the mutated 
KRAS oncogene) for growth inhibition of pancreatic tumors in a mouse model.
[92]
 It was 
found that encapsulated siG12D in LODER was active and stable for 155 days in vivo. 
Further, it was shown that these implants were capable of impeding the tumor growth and 
prolonging mouse survival time. This group also conducted a phase I and a phase II clinical 
trials for patients with unresectable locally advanced pancreatic cancer (LAPC). The siG12D 
LODER implant (implanted into the tumor using an endoscopic EUS biopsy needle) was 
combined with chemotherapy and the results showed that from twelve patients analyzed by 
CT scans, none showed tumor progression and most of them (10/12) demonstrated stable 
disease. Tumor marker CA19-9 was observed to decrease in 70% of patients and 18 month 
survival rate was 38.5%.
[93]
     
Recently, in a ground breaking study, researchers have tried to treat the pancreatic ductal 
adenocarcinoma (PDAC) by developing a tunable PLGA-based platform that enabled local 
delivery of anticancer drugs to the targeted tumor tissue (Figure 5).
[29]
 Accordingly, a PLGA 
solution mixed with PTX was cast on top of a stainless steel disc containing a suture hole. The 
resulting PTX eluting device (PED) was sutured onto the tumor surface in mouse xenograft 
model (different PDAC cell lines with different sensitivity to PTX). The results suggested that 
thickness of the PLGA layer had a direct impact on PTX released, in that thicker layers 
yielded higher and longer release when compared against thinner layers. In vivo this implant 
showed up to 12-fold increase in suppression of tumor growth (PDAC-3 tumors with highest 
sensitivity to PTX), caused longer survival of mice and reduced retention in non-target organs 
in comparison with the group that received IV PTX. Finally, in another study, researchers 
have fabricated DOX loaded PLGA cylindrical millirods by casting the polymer and drug 
mixture into a Teflon tube via deploying heat/compression.
[94]
 The millirods were implanted 
in the center of VX2 liver tumors in rabbits and the results showed that these implants were 
capable of significantly reducing the tumor size when compared to untreated controls. 
Furthermore, histological examinations revealed that necrosis happened throughout the tumor, 
however, some viable tumor cells were observed advancing beyond the main front of the 
tumor due to their lack of exposure to therapeutic drug concentration. 
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PCL: 
PCL is yet another biocompatible polyester that has semicrystalline structure with a glass 
transition temperature (Tg) of -60 ºC. Therefore it has highly flexible mechanical properties at 
room temperature which is the reason it was extensively exploited in various biomedical 
applications.
[95]
 This polymer has even slower degradation rate than PLA, due to presence of 
five hydrophobic –CH2 moieties in its repeating unit and consequently it can be 
copolymerized with other hydrophilic polymers to improve its biodegradation.
[96, 97] 
 
Nevertheless, owing to its slow degradation as well as its compatibility with a wide range of 
drugs, it was shown to facilitate drug release up to several months and it was used to 
fabricated anti-cancer implantable DDSs.
[97]
For example, injection molding was used to 
fabricate PCL made needle-shaped conical implants that were loaded with 5-FU to abrogate 
breast tumors in a mousemodel.
[98]
 Owing to the specific design of these implants they were 
capable of being injected directly into the tumor using a puncture needle that eliminated the 
need for invasive surgery. Moreover, in vivo tests revealed that these implants were capable of 
significantly preventing tumor growth as they could provide higher regional drug 
concentration compared with those in mice that did not receive any treatment or only received 
intravenous injections of the drug.
 
 
Poly(1,3-bis-(p-carboxyphenoxy propane)-co-(sebacicanhydride))(PCPP-SA): 
PCPP-SA (20:80 molar ratio) is an extremely hydrophobic copolymer that possesses surface-
controlled erosion and hence it was used to fabricate Gliadel wafers for treatment of brain 
tumors in several clinical studies.
[99, 100] 
 These wafers were fabricated in a two-step process, 
where initially they were dissolved in an organic solvent along with carmustine (BCNU) and 
subsequently spray-dried into microparticles that were eventually made into wafers using 
compression molding.
[4]
  
So far several preclinical in vivo studies were performed by loading these wafers with 
carmustine,
[101]
 or other anti-cancer agents such as PTX,
[102]
 4-
Hydroperoxycyclophosphamide (4-HC) 
[103]
, DOX,
[104]
 3-bromopyruvate (3-BrPA) and 
dichloracetate (DCA),
[105]
 and subsequently implanting them intracranially against malignant 
glioma. For instance, one study in rat brain revealed that carmustine loaded wafers were 
capable of releasing carmustine over a time span of five days and they were ultimately fully 
degraded 6-8 weeks after implantation 
[101]
.
 
In another study PTX-loaded wafers were used for 
treatment of malignant glioma in rat brain and it was observed that PTX-loaded wafers 
improved the median survival of rats to different degrees depending on concentration of 
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loaded PTX.
[102]
 Further, it was found that these wafers provided a much higher PTX 
concentration in the brain tissue proximal to the implant (75-125 ng taxol/mg brain tissue) 
than more distant sites (4 ng taxol/mg brain tissue). Fung et al., also carried out a 
pharmacokinetic study on interstitial delivery of carmustine, 4-HC, and PTX from the wafers 
in the monkey brain which showed high drug concentration (0.5-3.5 mM for carmustine, 0.3-
0.4 mM for 4-HC, and 0.2-1.0 mM for PTX) within first 3 mm from the implant and fairly 
lower concentration at 5 cm from the implant (0.4 µM for carmustine, 3 µM for 4-HC, and 0.6 
µM for PTX) after 30 days from implantation.
[103]
 Using area under concentration-time curve 
(AUC), it was also found that tissue exposure to carmustine by using implants were 4-1200 
times higher than that achieved by IV administration of a higher dose. Lastly, another group 
of researchers investigated delivery of 3-BrPA and DCA using the wafers (both a as 
monotherapy or in combination with oral administration of temozolomide (TMZ) and 
radiation therapy (XRT)), in rat models with gliosarcoma.
[105]
 The results showed that 
intracranial implantation of 5% 3-BrPA wafers and 50% DCA wafers led to significant 
improvement in median survival of animals, 18 days for 5% 3-BrPA wafers and 17 days for  
50% DCA wafers, when compared to the control group that did not receive any treatment (13 
days). Furthermore, combination of 5% 3-BrPA wafers and TMZ markedly improved the 
survival when compared to either therapy alone. Though triple combination therapy of wafers 
with TMZ and XRT did not show any statistical advantages in survival, however, 5% 3-BrPA 
wafers given on day 0 in combination with TMZ and XRT resulted in long-term survivorship 
of 30%.           
In addition, numerous clinical studies for treatment of malignant glioma with gliadel wafers 
(as adjunct to surgery and irradiation) showed notable increase in median survival time for 
patients with both primary and recurrent disease 
[106-109]
, which ultimately gained these wafers 
FDA approval in 1997 for the treatment of recurrent malignant glioma. However, 
complications still remain, some of the most common side effects of these wafers in clinical 
trials included: seizures, intracranial hypertension, impaired neurosurgical wound healing, 
meningitis, wafer migration and  poor drug penetration .
[110, 111] 
             
 
Poly(glycerol monostearate-co-ε-caprolactone) (PGC-C18): 
PGC-C18 is a super-hydrophobic, biocompatible copolymer of caproic acid and glycerol 
functionalized with stearic acid.
[112]
 Conjugation of hydrophobic side chains (stearic acid) 
imparts a large amount of hydrophobicity into this copolymer which makes it a suitable 
candidate for fabricating DDSs capable of delivery of anti-cancer drugs over an extended 
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period of time.
[113]
 Consequently, Liu et al., fabricated PTX loaded PGC-C18 polymeric films 
for prevention of local tumor recurrence after resection in a mouse model with lewis lung 
carcinoma (LLC) tumor.
[72] 
In vitro drug release evaluation showed that the drug loaded film 
released the PTX over several weeks and in vivo results revealed that PTX loaded films 
prevented local tumor recurrence in 83.3 % of animals compared with 22.2 % for systemically 
administered drug. Additionally, after 10 days, drug loaded films demonstrated a significantly 
greater PTX concentration (3000-fold) at the site of resection when compared to that for 
systemic injection of PTX with equal concentration. The same group used these PTX loaded 
films to reduce locoregional recurrence of chondrosarcoma, in mice xenograft model, 
following macroscopically complete  tumor resection.
[71]
 Based on in vivo observations, it was 
found that in mice treated with PTX-loaded films locoregional recurrence was 17 %  which 
was much lower than this value for PTX IV treated mice (89 %). Furthermore, animals treated 
with PTX-loaded films showed longer median overall survival (81 days) compared to PTX IV 
treated animals (48 days), which was due to higher concentration of PTX in the local tissue. 
In another study, PGC-C18 films loaded with anti-cancer agent 10-hydroxycamptothecin 
(HCPT) were used to prevent local growth and proliferation of LLC tumor in mice model.
[114]
 
Drug-loaded films were applied to a collagen-based scaffold to form a flexible composite that 
can be administered to resection margins of soft tissue via application of a surgical stapler. In 
vitro, HCPT-loaded composites released the drug over a period of seven weeks and in vivo 
observations revealed that animals treated with HCPT-loaded composites had much higher 
freedom from tumor growth (86 %) compared to animals that received larger intravenous dose 
of HCPT (0 %). Moreover, histological analysis of tissues at the surgical site showed normal 
wound healing process indicating the nontoxic nature of this composite.        
 
   
 
Poly(N-isopropylacrylamide) (pNIPAAm): 
poly(N-isopropylacrylamide) is a non-biodegradable polymer that due to its sharp phase 
transition at above 32 ºC (in pure water), has been extensively investigated in 
thermosreversible hydrogels.
[115]
 This phase transition above lower critical solution 
temperature (LCST) is caused by a reversible conformation transition from an extended coiled 
state to compact globular structure, that can be observed through abrupt shrinkage of the 
gel.
[116]
 The LCST of NIPAAm polymers can be tuned by copolymerizing it with monomers 
with different degrees of hydrophobicity; for instance, copolymerization with more 
hydrophobic monomer will decrease the LCST.
[117, 118]
 Recently, NIPAAM-based hydrogels 
have gained attention in instituting anti-cancer DDSs. for example, a thermo-sensitive hybrid 
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hydrogel comprised of methoxylpoly(ethylene glycol)-poly(ε-caprolactone)-acryloyl (PECA), 
glycidylmethacrylated chitooligosaccharide (COS-GMA), N-isopropylacrylamide (NIPAm), 
and acrylamide (AAm) was synthesized (abbreviated as PCNA) and subsequently loaded with 
DOX and gold nanorods (GNRs) for prevention of post-operative recurrence of breast cancer 
(Figure 6).
[119]
 A NIR laser was used to initiate the release of DOX by utilizing photothermal 
effect of GNRs which caused contraction of the thermo-sensitive hydrogel. In vitro, these 
hydrogels released the DOX by dual stimuli of NIR irradiation and pH. Additionally, 
subcutaneous implantation of composites into the mice showed complete degradation of 
hydrogels (due to inclusion of COS) with no inflammation after 35 days which indicated their 
biocompatibility. Lastly, complete resection of breast cancer tumors in mice followed by 
implantation of hydrogels at the original tumor site showed that after NIR irradiation DOX-
PCNA-GNR hydrogels markedly reduced tumor recurrence to 16.7 %, compared with 100 % 
for IV DOX administration, which was assumed to be a result of synergistic effects of 
photothermal therapy (PTT) and chemotherapy. 
 
 
Polyurethane (PU): 
PU elastomers are synthesized via a reaction between isocyanates and diols to form urethane 
linkages (-NH-COO-) in their main chains and as a result of their biocompatibility and 
mechanical flexibility, they have been used in variety of biomedical applications including as 
anticancer DDSs.
[120] 
For example, gemcitabine loaded PU films (GEM-PU) were used for 
treatment of colon cancer in a mouse model.
[121]
 In this study, poloxamer 407 (PL) was used 
as a release modifier in the PU membranes (GEM-PU-PL) and it showed substantial effect on 
release of GEM, as membranes with higher amounts of PL demonstrated faster release when 
compared to the ones with lower rates of PL or pure PU. Furthermore, in vivo results on 
tumor-bearing mice revealed that implants with highest amount of PL (namely GEM-PU-PL 
12%) were capable of totally inhibiting tumor-growth and even completely regress them.  
 
Ethylene-vinyl acetate (EVA):   
EVA is a biocompatible, non-degradable, inexpensive thermoplastic copolymer of ethylene 
and vinyl acetate (VA), which also has FDA approval.
[122, 123]
 VA content in the copolymer 
plays a crucial role in determining key properties of the polymer including polarity, 
crystallinity and mechanical properties.
[122]
 As a consequence of its desirable properties, drug-
loaded EVA films were used as a stent coating to facilitate anti-cancer drug delivery as well 
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as creating physical barrier against cancer cell ingrowth.
[123]
 For instance, a PTX or 5-FU 
loaded (EVA) film was developed to cover an esophageal stent for the treatment of 
esophageal cancer.
[124]
 These films possessed a double layer structure where the first layer 
(backing layer) was composed of pure EVA film and the top layer was comprised of drug 
loaded EVA films, which were attached together under employment of pressure and 
temperature. This unique structure allowed the permeation of drug from the top layer which 
was in contact with the tumor tissue and prevented the leakage of drug toward the lumen of 
stent. In vivo implantation of these stents into the porcine esophagus showed that after a 
period of 95 days only a small amount of drug was released from the back layer of the stent,   
the majority of drug permeated from the top side of the film. In addition, this drug-loaded 
implant did not cause any systemic or local toxicity and it also inhibited the tissue response 
including inflammation, ulceration and hyperplasia, which indicated its potential as a nontoxic 
treatment modality for patients suffering from esophageal cancer.  
 
 
2.1.2 Electrospun implants  
 
Electrospinning involves the usage of a strong electric field to create fibers (with diameter 
ranging from micrometers down to tens of nanometers) by extruding a polymer solution from 
an injection needle and depositing them on a collector plate.
[125-128]
 The electrospun fibers can 
vary in size and orientation (randomly distributed or aligned) based on the deployed 
processing parameters such as polymer solution flow rate, applied electric voltage, collector 
configuration (stationary or rotary), needle-tip-to-collector distance and needle size.
[129, 130]
 As 
a consequence of the many interesting properties of electrospun fibers, including high specific 
surface area and tunable porosity, they have been frequently utilized as implantable depots for 
drug delivery.
[125, 131, 132]  
One of the outstanding features of electrospinning is its ability to 
create multiaxial fibers comprised of a core (which can be drug loaded) and a sheath/multiple 
sheaths (that can retard the release of drug from the core and can also be loaded with drug) 
and as a result these multiaxial fibers have recently gained attention for controlled drug 
delivery.
[133-139] 
Despite these properties, the use of electrospinning  is limited in terms of 
fabrication of 3D implants with complex shapes and geometries, and not all biopolymers are 
spinnable with this technique.
[129, 140] 
Nevertheless, over the past decade electrospun fibrous 
mats, fabricated from a variety of biopolymers, have been largely used as DDSs for 
abrogation of malignant tumors or preventing their reoccurrence in numerous studies.
[141]  
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PLA and PLGA: 
PLA and PLGA were shown to be ideal choices of polymers for fabrication of electrospun 
fibers, mainly due to their solubility in volatile chlorinated and fluorinated solvents as well as 
their availability in a wide range of molecular weights, which allowed ease of electrospinning 
of these polymers.
[142, 143] 
 Electrospun PLA and PLGA mats have been frequently used as 
DDSs for cancer therapy.
[144]
 For example, electrospun PLA nanofibers that were loaded with 
DOX and used as local delivery systems against two types of secondary hepatic carcinoma 
(SHCC), namely nodular and diffuse SHCC (NSHCC and DSHCC), in mice.
[31]
 The in vivo 
results showed that targeting NSHCC tumors with DOX loaded fibers led to significant 
suppression of NSHCC growth and increased the median survival time of mice with DSHCC 
from 14 days to 38 days. In another study, Ding et al., Loaded the poly-D,L-lactide (PDLLA) 
nanofibers with docetaxel (DTX) to prevent breast cancer reoccurrence in mouse model.
[34]
 It 
was shown that animals treated with drug loaded membranes had significant decrease in 
locoregional reoccurrence after primary tumor resection (16.7%) when compared to systemic 
administered DTX (75.0%) or local administered DTX (77.8%). Additionally these drug 
loaded membranes showed minimal signs of inflammation in the surrounding tissue indicating 
a high level of biocompatibility. Similarly, other researchers investigated the inhibitory effect 
of released DCA from PLA electrospun mats to suppress cervical carcinoma in tumor-bearing 
mice.
[145]
 In vivo observations after 19 days showed a significant suppression of tumor growth 
in animals treated with drug loaded fibers as well as substantial reduction of tumor weight. 
This was assumed to be a result of synergistic necrosis of tumor cells by two different 
necroptosis mechanisms that were caused by high dosage of DCA. In a different study, (5-
FU)-loaded PLLA nanofibrous membranes were developed for suppressing colorectal cancer 
in xenografted mice.
[146]
 In vivo it was shown that these membranes were more capable of 
supressing tumor growth than an intraperitoneal injection of 5-FU (at median lethal dose 
(LD50) concentration) due to prolonged and continuous release of 5-FU from the membranes. 
PLA fibers can also be loaded with multiple chemotherapeutic agents to treat cancer in a 
combinatorial manner. For instance, Zhang et al., evaluated the in vivo activity of PLA fibers 
containing 5-FU and oxaliplatin (Oxa) against colorectal cancer (CRC) in tumor-bearing 
mice.
[147] 
As a result, it was shown that drug loaded fibers can significantly inhibit tumor 
growth due to higher local drug dose, caused by a sustained drug release from the fibers. 
Additionally, histopathological studies of the excised tumor tissue showed large areas of 
necrotic regions in the tumors after treatment with drug loaded fibers which was in great 
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correspondence with immunohistochemistry results of apoptosis related proteins (namely Bax 
and Bcl-2). 
  
PLA fibers could also be arranged in a multilayer structure to bring about controlled release of 
the drugs. As an example, Liu et al., fabricated asymmetric multilayer PLA nanofibers 
(AMPN) loaded with Oxa or a combination of Oxa and cyclophosphamide monohydrate 
(OxCy) to prevent liver cancer recurrence in mice models with either subcutaneous or 
orthotopic hepatocellular carcinoma (HCC).
[39]
 Three different types of multi-layered 
electrospun mats were fabricated, two layered (M2), three layered (M3) and five layered (M5) 
(Figure 7). Insertion of Oxa loaded multilayered membranes into the cavity, formed as a 
result of “subcutaneous tumor” removal, substantially slowed the rate of tumor reoccurrence 
and it increased the survival rate of the rodents compared to control group. Furthermore, in 
orthotopic HCC models wrapping of AMPN mats (loaded with OxCy) around the left liver 
lobe following partial hepatectomy revealed appearance of normal liver tissue without visible 
tumor reoccurrence in comparison to control groups, which was further confirmed by 
histopathological observations of liver samples. Similarly, the same group successfully 
fabricated other multilayered PLA electrospun mats loaded with cisplatin or Oxa/DCA that 
prevented local liver cancer or cervical cancer reoccurrence in mice models, respectively.
[35, 
37]
 Last but not least, to allow loading of hydrophilic drugs into PLA-based fibers, this 
polymer has been mixed with more hydrophilic polymers and subsequently electrospun to 
make fibers with improved hydrophilicity. For instance, cisplatin loaded mucoadhesive 
nanofibers made out of a mixture of PLA and polyethylene oxide (PEO) were fabricated to 
abrogate cervical/vaginal cancer in mice.
[36]
 Owing to the hydrophilicity properties of PEO 
these nanofibers showed good in vivo vaginal retention and upon implantation into the vagina 
of mice, cisplatin concentration was found to be much higher in vagina/cervix region that in 
the non-target organs, in contrast to the case of IV cisplatin. However, these nanofibers did 
not show superiority over IV cisplatin in treating vaginal tumors. Consequently, in a separate 
study the same group co-loaded the PLA/PEO nanofibers with cisplatin and curcumin (cis-
cur) to prevent cervical cancer reoccurrence after surgery.
[32]
 After resection of subcutaneous 
vaginal tumors drug loaded fibers were implanted at the site of tumor resection and it was 
shown that these fibers were better capable of preventing local cervical cancer reoccurrence 
when compared to IV drugs, which was further supported by histological analysis showing 
large area of necrosis induced by cis-cur/fibers only 4 days after tumor resection. 
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As highlighted in the beginning of this section, PLGA has also been used in fabricating anti-
cancer fibrous DDSs. For example, Ranganath et al., fabricated submicron (F2) and nanoscale 
(F3) discs from PLGA(50:50) electrospun fibers loaded with PTX and used them for 
inhibiting growth of glioblastoma in a mouse model.
[148]
 Consequently, F3 nanofibrous discs 
demonstrated a greater drug release rate in vitro and in vivo, in comparison to counterparts 
including F2 submicron fibrous discs and PTX-loaded PLGA microspheres entrapped in 
sodium alginate beads. As a result, F3 discs showed higher drug availability and subsequently 
enhanced diffusion rate as well as diffusion distance in the mouse brain tissue that is crucial 
considering that glioblastoma multiforme (GBM) typically reoccurs within 2 cm of the 
resection site. Moreover, F3 discs were capable of inhibiting the tumor at its early stages of 
tumor growth as a consequence of high local drug concentration, which is critical to slow 
down the reoccurrence rate of glioma in post-surgical chemotherapy. In another study carried 
out by Tseng et al., PLGA nanofibrous membranes were loaded with combination of drugs 
including BCNU, irinotecan and cisplatin to treat malignant glioma in tumor-bearing rats.
[149]
 
Consequently, in rats treated with drug loaded fibers (BIC/PLGA), a substantially higher 
concentration of drugs was observed in brain tissue than in the blood throughout 8 weeks of 
study. Rats treated with BIC/PLGA membranes experienced a much lower tumor volume 
after 16 days, when compared to that in rats which received blank PLGA membranes. 
Furthermore, in the BIC/PLGA treated group a much longer median survival time was 
achieved (~60 days) in comparison to the group treated with non-drug loaded (blank) 
membranes (~22 days).   
  
PCL: 
Due to specific rheological and viscoelastic properties of PCL this polymer and its 
copolymers have been successfully utilized in electrospinning to bring about fibrous mats.
[150]
 
Similar to PLA and PLGA, PCL fibers were also utilized as drug carriers for local delivery of 
anti-cancer drugs to tumor site. For instance, Chen et al., made nanofibers from combination 
of PCL and gelatin (PG), that contained DOX-loaded core-shell nanoparticles of Cu9S5-
mesoporous SiO2 (Cu9S5@mSiO2) and used them for synergistic chemo- and photothermal 
therapy of hepatoma tumors in mice (Figure 8).
[151] 
In vitro DOX release in PBS (phosphate-
based buffer) revealed that these fibrous membranes possessed pH responsive release owing 
to intrinsic properties of Cu9S5@mSiO2 nanoparticles, also, it was shown that after 5 min laser 
irradiation the temperature of Cu9S5@mSiO2 PG fibers dramatically increased from 21 ºC to 
54.6 ºC. Additionally, in vivo results showed that DOX-loaded Cu9S5@mSiO2 PG composite 
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fibers under laser irradiation had a more efficient tumor suppression effect once compared 
against single photothermal therapy of tumors by Cu9S5@mSiO2 PG fibers or with single 
chemotherapy by Dox loaded Cu9S5@mSiO2 PG fibers. In another study the same group 
fabricated similar PG nanofibers instead loaded them with DOX-containing 
NaGdF4:Yb/Er@NaGdF4:Yb@mSiO2-PEG core-shell nanoparticles (upconverting 
nanoparticles; UCNPs) and indomethacin (anti-inflammatory drug) to abrogate hepatoma 
tumors in mice.
[33]
 This composite fiber  not only was aimed for controlled-release of DOX 
but also enabled upconversion fluorescence/magnetic resonance dual-modality imaging via 
NaGdF4:Yb/Er@NaGdF4:Yb incorporated into composite fibers. In vivo anti-tumor efficacy 
showed that composite fibers containing DOX-loaded UCNPs and indomethacin had the 
highest tumor inhibition rate (96%) when compared to simple DOX-loaded fibers (61.8%). 
Moreover, owing to presence of indomethacin in composite fibers, they caused complete 
healing of surgical wound. At last, in an attempt to further prolong the drug release of PCL 
nanofibers, researchers fabricated cisplatin-loaded superhydrophobic electrospun nanofibers 
from mixture of PCL and Poly(caprolactone-co-glycerol-monostearate) (PGC-C18) for 
prevention of local cancer reoccurrence post resection in mice model with lung carcinoma.
[152]
 
Owing to hydrophobicity of these nanofibers they have shown a sustained release of drug 
over 90 days. Further, in vivo evaluation showed that these fibers were capable of 
significantly increasing median reoccurrence-free survival rate to more than 23 days 
compared to the group treated with intraperitoneal injection of cisplatin which all died before 
day 16 due to cancer recurrence. 
  
Gelatin: 
Owing to superior biocompatibility and biodegradability of gelatin, this polymer was 
extensively utilized to fabricate electrospun fibers (either alone or as a blend component) for 
various biomedical applications including drug delivery.
[131, 153]
 For instance, Yang et al., 
fabricated core-shell fibers, in which the core was comprised of polyvinyl alcohol (PVA) 
containing folate-decorated micelles (FM) of poly(ε-caprolactone)-poly(ethylene glycol) 
loaded with DOX (for active targeting of solid tumors), and the shell contained genipin 
crosslinked gelatin (Figure 9).
[139]
 These fibers showed delayed in vitro release of DOX when 
compared with micelles alone, and further in vivo studies in mice with  breast cancer revealed 
that DOX accumulation in tumors for FM (IV administrated) and FM-nanofiber groups 
(implanted near the tumor) were significantly higher than that in DOX treated (IV 
administrated) group. Moreover, during 21 days of treatment, groups treated with FM-
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nanofiber showed comparable tumor growth suppression in comparison to the groups that 
received four times injection of DOX or M or FM. Lastly, FM-nanofiber treated group 
experienced a higher survival rate when compared to other groups, owing to lower systemic 
drug exposure caused by local delivery of DOX using the nanofibers.  
 
Polyurethane (PU): 
On account of biocompatibility and excellent mechanical properties of PU electrospun fibers, 
they have been recently exploited as anti-cancer DDSs. For instance, a PTX-eluting 
polyurethane electrospun membrane was fabricated for inhibiting the growth of colon cancer 
in a tumor-bearing mouse model.
[154]
 These PTX-eluting nanofiber membranes (PTX-NFM) 
showed sustained release of PTX for 30 days in both PBS buffer and PBS buffer with bile 
extract. Additionally, implantation of these fibers next to colon carcinoma tumors in mice 
resulted in significant inhibition of tumor growth when compared with the group treated with 
sub-tumoral injection of PTX (PTX-INJ). Moreover, mice treated with PTX-NFM showed 
sustained intratumoral concentration of PTX until 21 days after implantation in contrast to 
PTX-INJ treated group which showed almost no PTX within tumor tissue only 7 days after 
injection.       
 
2.1.3 3D printed implants 
 
3D printing  is known as a process whereby three dimensional solid objects of any shape are 
constructed from a computer-aided design (CAD) model via layer-by-layer deposition of 
materials onto a computer-controlled built platform.
[127, 155] 
Technically, 3D printing 
encompasses various technologies such as inkjet printing, microextrusion printing, laser-
assisted printing, stereolithography and fused deposition modeling (FDM), and they all offer 
significant advantages over traditional fabrication methods as they endow reliability, 
reproducibility and flexibility in design (geometrically complex shapes).
[155-157]
 In the context 
of cancer studies 3D printing has been used to recreate the 3D microenvironment of tumors by 
printing a variety of hydrogels and this aspect of 3D printing will not be reviewed here.
[158-160]
 
Herein, we solely focus on bipolymeric anti-cancer drug eluting implants fabricated using 3D 
printing technologies.  
3D printed DDSs are commonly fabricated via microextrusion or FDM printing.
[161]
 
Microextrusion printing involves continuous extrusion of biomaterials (in the form of 
solution/paste) from a temperature-controlled micro-extrusion head to a building platform, 
  
20 
 
using pneumatic pressure or piston-assisted system, for layer-by-layer fabrication of 3D 
constructs.
[127, 162]
 FDM deploys preformed filaments fed into a temperature-controlled 
extruder where they are heated and subsequently the semi-molten thermoplastic is deposited 
onto a platform in a layer by layer process.
[163, 164] 
Such printing is directly affected by 
processing parameters such as nozzle diameter and temperature, feed rate and print head 
speed.
[165, 166]
 Interlayer bonding significantly affects the final properties of the printed 
product and consequently solidification procedures should be carefully controlled to avoid 
separation of subsequent layers. The major disadvantages of extrusion and FDM printing 
include: slow printing speed, nozzle clogging and interlayer debonding.
[167]
 Even so, these 
methods have been successfully practiced on biopolymers such as PCL and PLGA to fabricate 
implantable anti-cancer DDSs.  
 
 
PLGA and PCL: 
Owing to the thermoplastic nature of PCL and PLGA in conjunction with their favorable 
biocompatibility and biodegradability, they have been utilized to create 3D printed DDSs for 
cancer therapy. For example, most recently extrusion printing was used to fabricate a 3D 
patch made from a mixture of PLGA (lactide:glycolide = 85:15) and PCL loaded with 5-FU 
for growth suppression of pancreatic cancer (Figure 10).
[27]
 The patches were printed with 
three different pore shapes and geometries (latticed, slant and triangular) in different 
thicknesses and it was found that these features can greatly affect the drug release profile by 
altering the surface area:volume ratio (S:V) of the structure. Implantation of drug-loaded 
patches (P100;100 mg 5-FU and P150;150 mg 5-FU) underneath a pancreatic cancer tumor in 
mice, resulted in a substantial decrease in tumor size when compared to non-drug loaded 
patch (P0) groups. In another study, Sun and his colleagues fabricated a PCL scaffold using a 
FDM printer and coated the structure with a mixture of chitosan, chitosan-modified 
montmorillonite clay and β-tricalcium phosphate (β-TCP) which was subsequently coated 
with DOX solution (DESCLAYMR_DOX) to inhibit growth of breast tumors in mice .
[28]
 
These drug eluting implants showed a significant burst release of DOX in the first 24 h that 
was followed by four weeks of sustained release. Further, subcutaneous implantation of 
DESCLAYMR_DOX in mice showed prolonged presence of DOX to a much larger extent at 
the treatment site which resulted in higher tumor growth inhibition when compared to 
subcutaneous injection of DOX (INJECTION_DOX). Also compared to INJECTION_DOX, 
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DESCLAYMR_DOX showed decreased multi-organ metastasis as well as cardiotoxicity due 
to local delivery of DOX. 
 
2.2 Injectable in-situ forming implants 
 
Injectable DDSs are typically made from a solution/semisolid mixture of polymer matrix and 
therapeutic agents that solidify in situ upon injection into the tumor site. 
[10, 15, 168]
 The 
solidification mechanism will differ based on the type of biopolymer used, however, the 
existing injectable DDSs can be generally categorized accordingly
[168-170]
: (I) in situ 
precipitation, wherein the polymer precipitates from a solution state as a consequence of 
solvent removal 
[171, 172]
, sol-gel transition in response to temperature change
[40, 41, 43]
 or pH 
change
[42, 173]
; (II) in situ crosslinking, wherein the polymer chains undergo physical/chemical 
cross-linking upon injection as a result of covalent bonding  
[53, 55, 174-177]
 , or non-covalent 
bonding of polymeric chains.
[50, 51, 54]
 The injectable implants hold great advantages over 
preformed implants including elimination of invasive surgical intervention and their ability to 
fill any cavity, into which they are injected.
[178-180] 
Some of the disadvantages of these 
implants are the complicated and sometimes toxic crosslinking chemistry required as well as 
the fairly long gelation time upon injection.
[168]
 Nevertheless, recently injectable DDSs, 
developed from a broad range of biopolymers, have been extensively used to inhibit the 
growth of malignant tumors or prevent their recurrence in preclinical and clinical studies.
[181] 
 
 
Polyethylene glycol (PEG): 
PEG is a FDA-approved synthetic hydrophilic polymer that has various structures including 
linear and branched (multi-arm or star-shaped).
[182]
 Aside from its desirable properties such as 
good biocompatibility and non-immunogenity, this polymer is capable of being chemically 
modified with various functional groups (via replacement of two hydroxyl groups in its 
repeating unit) to provide certain functionalities.
[183, 184]
 Consequently, PEG and its 
copolymers have been frequently used to bring about injectable DDSs based on either in situ 
precipitation or in situ crosslinking mechanisms. PEG-based injectable hydrogels established 
via in situ precipitation are often thermo-gelling hydrogels that have been synthesized via 
copolymerization of PEG with other polymers to allow sol-gel transition of the hydrogel upon 
changes in temperature. For instance, DOX-loaded nanoparticles made from copolymer of 
poly(ε-caprolactone-co-1,4,8,trioxa[4.6]spiro-9-undecanone)-poly(ethylene glycol)-poly(ε-
caprolactone-co-1,4,8, trioxa[4.6]spiro-9-undecanone) (PECT) have formed the macroscale 
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hydrogel upon thermo-sensitive self-aggregation of PECT/DOX nanoparticles at 37 °C in 
aqueous media (Figure 11).
[41] 
 Peritumoral injection of PECT/DOX hydrogel into the breast 
tumors of mice showed a much higher intratumoural concentration of DOX when compared 
to other organs, which in turn led to greater suppression of tumor growth. In addition, survival 
rate increased in animals treated with PECT/DOX hydrogel compared to ones who received 
IV injection of DOX or PECT/DOX NPs, which was largely due to the fact that hydrogels 
were capable of locally releasing DOX within the tumor area, preventing distribution of DOX 
to other organs. Researchers developed another thermo-sensitive hydrogel from MPEG-b-
(PCL-PLLA) diblock copolymer  loaded with 5-FU that underwent an instantaneous sol-gel 
transition at body temperature.
[185]
 Intratumoral injection of this system into melanoma tumors 
in mice showed higher tumor suppression effect and subsequent necrosis of tumor tissue 
which was comparable to that of mice who received three intratumoral injections of free 5-FU, 
each at equivalent concentrations to that of one hydrogel injection. Similarly, Phan et al., 
synthesized a thermo-sensitive triblock copolymer of poly(ε-caprolactone-co-lactide)-b-
poly(ethylene glycol)-b-poly(ε-caprolactone-co-lactide) (PCLA-PEG-PCLA) that was used to 
develop an injectable hydrogel containing nanoparticles of montmorillonite loaded with 
gemcitabine (MMT-GEM).
[186]
 Interestingly, the targeted injection of this composite hydrogel 
into a pancreatic tumor (in mice) led to enhanced anti-tumor efficacy when compared to 
control group of intratumorally injected GEM solution at equivalent concentrations.  
Triblock copolymers of PLGA and PEG (PLGA-PEG-PLGA) are specifically attractive 
thermo-responsive systems on account of their biodegradability and acceptable safety profile 
and they showed to undergo sol-gel transition at physiological temperature (37 °C).
[187] 
As a 
result, this copolymer has been exploited as delivery systems for anti-cancer drug delivery 
purposes.
[188, 189]
 As an example, incorporation of DOX into this thermo-gel did not interfere 
with its sol-gel transition (except at high concentration of DOX; 4 mg/ml) and after injection 
of this drug loaded hydrogel in the vicinity of a sarcoma-tumor in mice, significant 
suppression of tumor growth as well as strong apoptosis of tumor cells were achieved.
 [190] 
 
Similarly, Zhang et al., used the same DOX loaded PLGA-PEG-PLGA thermo-gel and 
injected it into hepatic-tumor in mice.
[191] 
Interestingly, similar anti-tumor efficacy was 
observed in this case and toxicity studies revealed that these drug loaded hydrogels caused 
mild lesions in major organ tissues (heart, liver, spleen lung and kidney) when compared with 
DOX control group. The same gel was also loaded with PTX, also known as OncoGel, and 
used as palliative therapy in pre-clinical in vivo studies in rats with metastatic spinal 
tumors,
[192]
 mice with breast carcinoma 
[193]
 and porcine model for future application in non-
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resectable pancreatic ductal adenocarcinoma.
[194]  
Most importantly, a phase I clinical trial on 
patients with superficially accessible advanced solid tumors and a phase 2a clinical study on 
patients with inoperable esophageal cancer (OncoGel used in adjuvant to radiotherapy), 
showed that OncoGel administered intralesionally was well tolerated, retained its position at 
the site of injection and caused low systemic concentration of PTX.
[195, 196]
 Other types of 
PEG-based thermo-gelling copolymers include triblock copolymer of poly(ethyleneglycol)-
poly(ε-caprolactone)- poly(ethyleneglycol) (PEG-PCL-PEG, PECE) and triblock copolymer 
of poly(γ-ethyl-L-glutamate)-poly(ethylene glycol)-poly(γ-ethyl-L-glutamate) (PELG-PEG-
PELG). Both these copolymers form a gel quickly after being exposed to body temperature 
and they have been employed for local delivery of anti-cancer drugs in animal models.
[197, 198] 
For instance, Lei et al., loaded PECE with PTX and injected it at the original tumor site in 
4T1 breast cancer -bearing mice, with the intention of preventing locoregional recurrence of 
primary tumor after resection.
[47]
 As a result, recurrence of the tumor was significantly 
inhibited by administration of PTX-loaded PECE hydrogels (9.1%) compared with systemic 
(77.8%) or local (75%) administration of PTX at an equivalent concentration. In addition, this 
hydrogel accelerated post-operative wound healing at the surgical incision site, indicating its 
superior biocompatibility. In another work, Cheng et al., loaded PELG-PEG-PELG thermo-
gels with PTX and used it for local delivery of PTX to liver carcinoma in mice models.
[199]
 
Interestingly, it was shown that by adjusting the length of each block in the copolymer a 
different sol-gel transition temperature could be achieved. Injection of PTX loaded PELG-
PEG-PELG hydrogel beside the tumor revealed enhanced tumor growth suppression when 
compared to equivalent amounts of free PTX and higher anti-tumor activity that was 
confirmed by TUNEL staining of apoptotic cells. 
   
As it was highlighted at the beginning of this section PEG can also be used to bring about 
injectable hydrogels based on in situ crosslinking. This normally involves functionalization of 
PEG with a variety of desirable functional groups, which are either mixed with a secondary 
polymer to facilitate the cross-linking, or can be used alone to enable radical/photo cross-
linking of the PEG chains.
[200, 201]
 For instance, Wang et al., used polydopamine nanoparticles 
(PDANPs) to cross-link thiol-terminated four-arm PEG (via thiol-ene reaction) and form a 
hydrogel that showed sensitivity towards NIR irradiation, owing to the presence of 
polydopamine (Figure 12).
[177]
 This feature was further used for controlled release of the drug 
as well as photothermal therapy of tumors. Upon intratumoral injection of 7-ethyl-10-
hydroxycamptothecin (SN38) loaded gel into a lung cancer  mouse model, it was found that 
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PDA-SN38/PEG gel with NIR radiation had greater anti-tumor activity when compared with 
the PDANP-SN38 group, due to synergistic interactions of the the chemo- and photothermal 
therapy. In addition, these gels caused no detectable pathological change in major organs 
indicating their minimal systemic toxicity. In another study, a heparin functionalized four-arm 
PEG hydrogel was synthesized which was further processed post-synthesis into injectable 
microparticle aggregates.
[49]
 Owing to the presence of heparin in these hydrogel 
microparticles they have shown high affinity towards DOX especially at higher 
concentrations, leading to slow in vitro release of this drug in PBS. Moreover, local injection 
of the DOX-loaded hydrogel microparticles into established human orthotopic breast tumours 
in miceshowed significant reduction in tumor burden as well as breast cancer metastasis when 
compared to IV bolus-treated animals.
 
 Li et al., used acylhydrazone bonds to form a pH-
sensitive injectable hydrogel from a mixture of dibenzaldehyde-terminated PEG (DF-PEG) 
and polyaspartylhydrazide (PAHy).
[42]
 In vitro, these hydrogels showed faster release of DOX 
in a buffer solution with acidic pH compared to a neutral pH due to cleavage of 
acylhydrazone bonds in acidic conditions. Furthermore, intratumoral injection of DOX-loaded 
hydrogel in fibrosarcoma tumor bearing mice showed a superior antitumor activity compared 
to control groups as well as negligible toxicity in vivo.  
Guest-host interactions have also been implemented to make PEG-based injectable hydrogels 
based on in situ crosslinking mechanism. For example, Kuang and his coworkers synthesized 
two types of nucleobase-terminated PEG (adenine and thymine) that upon mixing with α-
cyclodextrin (α-CD) formed an injectable hydrogel based on guest-host interactions.
[50]
 
Additionally, intratumoral injection of DOX loaded hydrogel into a cervical cancer  mouse 
model revealed that this hydrogel substantially restricted the tumor growth and caused no 
significant fluctuation in body weight (compared to control groups) which was assumed to be 
a consequence of slow and longer local release of DOX from this hydrogel. Similarly, the 
concept of guest-host interaction was used by another group to make an injectable 
biocompatible hydrogel by developing a mixture of methoxy polyethylene glycol (MPEG) 
conjugated with arginine-functionalized poly(L-lysine) Dendron and α-CD (MPEG-PLLD-
Arg), for delivery of MMP-9 short hairpin RNA plasmid (pMMP-9).
[52]
 In vitro, these 
hydrogels were capable of sustained release of pMMP-9 and after intratumoral injection of 
drug-loaded hydrogels in nasopharyngeal carcinoma tumor-bearing mice, it was shown that 
MPEG-PLLD-Arg/pMMP-9 hydrogels enhanced retention of pMMP-9  in the tumor 
compared to standard pMMP-9-loaded Polyethylenimine (PEI-25K/pMMP-9). Moreover, one 
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time injection of this new hydrogel had equivalent anti-tumor efficiency to seven injections of 
a conventional PEI-25K/pMMP-9 that totalled the plasmid concentration in the hydrogel. 
Wu et al., designed another injectable hydrogel based on Schiff-base interaction of aldehyde-
functionalized four-arm PEG (PFA) and 4-arm poly(ethylene glycol)-b-poly(L-lysine) (PPLL) 
for co-delivery of metformin (ME) and 5-FU.
[55] 
In vitro drug release and degradation studies 
showed that this hydrogel released both ME and 5-FU in a pH-sensitive manner. Moreover, a 
single subcutaneous injection injection of the drug loaded hydrogel (ME and 5-FU) beside the 
tumors of BALB/c mice bearing colon adenocarcinomas  led to significant anti-tumor activity 
compared to that of single and combination bolus drug doses, and this was a result of p53-
mediated G1 arrest and apoptosis of tumor cells caused by synergistic therapeutic effect of ME 
and 5-FU. Additionally, histological assessment of major organs in mice that were treated 
with blank (non-drug loaded) hydrogel revealed their excellent biocompatibility. And lastly, a 
photo-crosslinkable hydrogel made from polyethylene glycol dimethacrylate (PEG-DMA) 
was used for delivery of temozolomide-loaded polymeric micelles (M-TMZ) to brain tumors 
in mice.
[176]
 Drug-loaded hydrogel was intracranially injected into a human glioblastoma 
bearing xenograft mouse model and subsequently photo-crosslinked in situ. It was shown that 
the unloaded hydrogel did not cause any apoptosis in the brain of the mice, while the drug 
loaded hydrogel markedly decreased the tumor weight when compared to all the other control 
groups. Furthermore, histological analysis of tumors (retrieved seven days post-treatment) 
using CD34 and Ki67 staining, revealed that mice treated with in situ cross-linked drug-
loaded hydrogel showed no sign of cancer proliferating cells at the center of tumor but were 
present at the periphery. 
   
Pluronic F-127 (poloxamer 407): 
Triblock copolymers of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) 
(PEO-PPO-PEO) have been of great interest in drug delivery due to their gelation 
phenomenon,
[202-207]
 however among them pluronic F127 is reported to be the least toxic one 
and it also showed inhibitory effect against P-glycoprotein, a major player in the multidrug-
resistant phenotype in cancer.
[169, 208, 209]
 As a result, this polymer has gained much interest as 
DDS against malignant tumors.
[210-216] 
For instance, three different types of thermo-sensitive 
F-127 hydrogels were developed with either paclitaxel (PTX) in the form of molecules (MOs), 
nanocrystals (NCs) and microcrystals (MCs).
[40] 
Interestingly, in vitro erosion and release 
studies showed very small release of PTX from PTX-NCs-Gel and PTX-MCs-Gel whilst 
PTX-MOs-Gel showed the highest amount of release after 14 days in PBS which was in direct 
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correlation with their corresponding erosion rates. In addition, it was shown that PTX-MCs-
Gel possessed the highest intratumoral drug concentration followed by PTX-NCs-Gel and 
PTX-MOs-Gel, respectively. Lastly, PTX-NCs-Gel showed the highest anti-tumor efficacy 
against breast tumor xenografts in mice when compared with PTX-MCs-Gel and PTX-MOs-
Gel, which was assumed to be a consequence of sustained release of drug from PTX-NCs-Gel. 
In a separate study, Chen et al., attempted to improve the mechanical properties of pluronic F-
127 by copolymerzing it with hexamethylene diisocyanate (HDI-PF127) and subsequently 
mixing it with hyaluronic acid (HDI-PF127/HA).
[43]
 Hence, the mentioned hydrogel showed a 
sol-gel transition at 37 °C and after intratumoral injection of DOX-loaded gels in breast 
tumor-bearing mice, it was shown that DOX-loaded HDI-PF127/HA gel exhibited the highest 
tumor growth inhibition compared to DOX-loaded PF127/HA gel due to its slower 
degradation rate and controlled DOX release. Finally, Guo et al., synthesized linoleic acid 
(CLA)-couple poloxamer (CLA-c-P) thermo-sensitive hydrogel to benefit pro-drug activity of 
CLA and further increase stability of the hydrogel.
[46]
 Injection of PTX-loaded CLA-c-P 
hydrogel beside breast cancer tumor in mice model led to significant suppression of tumor 
growth when compared with control groups, as a result of the synergistic effect of CLA in 
conjugation with PTX. Moreover, significant reduction in expression of cell cycle signaling 
proteins (Cyclin A, Cyclin B, Cyclin D3 and CDK2) in combination with considerable 
increase in expression level of pro-apoptic protein caspase 3 verified cancer cell death in vivo. 
 
Poly(N-isopropylacrylamide) (pNIPAAm): 
As highlighted previously, pNIPAAm has recently attracted attention as a DDS for cancer 
treatment, mainly due to its phase transition from a hydrated state to a collapsed state above 
its LCST. However, this polymer by itself is not suitable to be used as injectable implants, 
mainly because injection of highly elastic hydrogels is impractical.
[217]
 Consequently, in order 
to give shear thinning behavior to this hydrogel, it was copolymerized or functionalized with 
secondary polymers, which also improved the biodegradability of the resulting gel.
 [218]
 
Nevertheless, pNIPAAm-based injectable hydrogels have lately gained a foothold in drug 
delivery.
[219-221] 
 For example, Zhou et al., developed a DOX loaded thermo-sensitive 
injectable hydrogel (with LCST of 33 °C) by attaching amine-terminated pNIPAAm to gelatin 
modified-single wall carbon nanotube (SWNT) and used this hydrogel for chemo-phototermal 
treatment of gastric cancer in a xenograftin mouse model of disease.
[219]
 In vitro this hydrogel 
showed a sustained release of DOX in PBS over a period of 28 days. In vivo experiments 
revealed that DOX loaded SWNT-GEL accompanied by NIR radiation had the highest tumor 
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growth inhibition compared to free DOX group (injected intratumorly) or SWNT-GEL group 
without NIR radiation, as a consequence of synergistic effect of DOX and hyperthermia. 
Furthermore, Hoechst (HE) staining of four major organs (heart, liver, kidney, spleen) after 28 
days of treatments with SWNT-GEL, showed no apparent organ damage, indicating good 
biocompatibility of this gel. Similarly, Xu and his colleagues, made a smart injectable 
nanocomposite hydrogel by copolymerizing NIPAAm and DOX loaded methacrylated poly-
β-cyclodextrin (MPCD), in presence of gold nanorods (GNRs), and subsequently used it for 
chemo-photothermal synergistic therapy of sarcoma in a mouse model.
[220]
 It was shown that 
mass ratio of monomers in the copolymer had a major effect on LCST of the resulting 
hydrogel. In vitro experiments in PBS revealed that the nanocomposite hydrogels were 
capable of releasing DOX in response to pH change or NIR radiation. Moreover, in vivo 
observations showed that animals treated with DOX loaded gel+NIR radiation experienced 
outstanding tumor growth suppression when compared with free DOX group, which was 
further confirmed by histopathological analysis of treated tumor tissues.  
 
 
Collagen: 
Collagen one of the most abundant proteins in the human body, has been extensively explored 
for biomedical applications.
[222]
 Collagen can undergo self-assembly to form injectable 
fibrous hydrogel based on non-covalent bonding.
[223]
 Consequently, collagen has gained 
attention as an injectable DDS for a variety of cancers. For example, a collagen peptide 
modified dendrimer attached to DOX via a hydrazone bond (CP-Dox-den) was synthesized 
and embedded in collagen gel.
 [224]
 Subsequent injection of this gel underneath a breast cancer 
tumor (in mice) led to prolonged suppression of tumor growth. Additionally, CP-Dox-den/Col 
gel was even capable of suppressing metastasis in tumor-bearing mice, as a result of sustained 
release of DOX from the gel over the period of the experiment. Peng et al., designed another 
injectable hydrogel from a mixture of collagen and Polyethylenimine (PEI) containing ld1-
targeted siRNA for gastric cancer inhibition.
[225] 
Consequently, collagen/PEI-siRNA gels 
showed slower and sustained release of siRNA owing to better stability of these gels 
compared to collagen-siRNA gels. Additionally, in vivo anti-cancer studies using a gastric 
cancer xenograft mouse model revealed that collagen/PEI-siRNA gel inhibited tumor growth 
to a greater degree compared with collagen-siRNA gels or siRNA/medium, which was further 
confirmed by immunostaining of treated tumor cells with cell-cycle antibodies (cyclin D1 and 
P21) and cell proliferation antigen (PCNA). Most recently, researchers developed an 
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injectable hydrogel from a mixture of collagen and gold nanoparticles (AuNPs) containing a 
photosensitizer (PS) for non-invasive combinational photodynamic therapy (PDT) and 
photothermal therapy (PTT) of breast cancer in mice (Figure 13).
[54]
 This hydrogel was 
formed due to ionic interactions of negatively charged [AuCl4]
-
 ions with positively charged 
collagen. Intratumoral injection of this hydrogel into tumor-bearing animals followed by 
irradiation using laser light resulted in up to an 80% elimination rate of tumors. In addition, 
the dual therapy caused suppression of tumor recurrence for a longer period of time when 
compared to monotherapies, denoting superior synergistic anti-cancer effect of photodynamic 
therapy and photo thermal therapy. 
Cisplatin/Epinephrine (CDDP/epi) gel is also an injectable hydrogel based on collagen matrix 
and it was exploited in several clinical studies in patients with esophageal cancer,
[226]
  
adenocarcinomas,
[227] 
squamous cell carcinomas 
[228]
 and hepatocellular Carcinoma.
[229]
 For 
instance, Monga et al., injected the CDDP/epi gel intratumorally (using endoscopy) in nine 
patients with esophageal cancer and it was found that this treatment restored swallowing in 8 
of nine patients, highlighting its palliative-therapy potential.
 [226]
   
 
Chitosan: 
Chitosan is a cationic linear polysaccharide composed of randomly distributed β-(1-4)-linked 
D-glucosamine and N-acetyl-D-glucosamine units, and on account of its intrinsic properties 
such as, biocompatibility, biodegradability, penetration enhancer (opening epithelial tight-
junction) and wound healing promoter, has received great deal of attention in medical and 
pharmaceutical applications.
[230, 231]
 Injectable chitosan-based hydrogels are generally made 
by neutralization of chitosan amine groups that eliminates the repulsive inter-chain 
electrostatic forces and allows development of extensive hydrogen bonding and hydrophobic 
interactions between chains, which eventually leads to formation of hydrated gel-like 
precipitate.
[232]
 Furthermore, it was shown that pH sensitive chitosan gels can be transformed 
into thermally sensitive gels by addition of polyol salts such as β-glycerophosphate (GP).
[116]
  
Injectable chitosan-based gels have shown great promise in local delivery of anti-cancer drugs. 
For instance, a thermo-sensitive injectable hydrogel containing chitosan and β-
glycerophosphate (C/GP) loaded with liposomal doxorubicin (LipDOX) was developed and 
showed pH-dependent release of DOX in in vitro settings.
[233]
 In vivo results from 
intratumoral injection of this gel into liver tumor-bearing mice showed that LipDOX+C/GP 
had a better anti-tumor effect and less systemic cytotoxicity when compared with DOX+C/GP 
gels, due to more sustained release of DOX from LipDOX+C/GP which caused a larger 
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therapeutic window. In another study, Hsiao et al., synthesized a chitosan derivative, which 
contained self-doped acid substituted polyaniline (PANI) side chain (NMPA-CS) that was 
capable of self-assembling into a micellar hydrogel upon local pH change (sol-gel transition at 
pH of 7).
[173]
 Interestingly, exposing NMPA-CS solution to NIR laser showed rapid increase 
in its temperature (to 54 °C) within 5 min of exposure and possessed excellent photostability. 
Subsequently, subcutaneous injection of this gel into the right flank of mice showed mild 
foreign-body reaction with slow degradation. Additionally, intratumoral injection of NMPA-
CS in liver cancer-bearing mice followed by NIR radiation (5 min every 4 days) led to 
effective suppression of tumor growth and maintained no sign of tumor progression for the 
duration of study, as a consequence of successful photothermal therapy of these tumors. Shi 
coworkers also made an injectable pH-sensitive hydrogel resulting from Schiff-base 
interaction of succinated chitosan (S-chi) and oxidized alginate (O-alg).
[174]
 This hydrogel 
showed faster in vitro release of DOX at lower pH in PBS and subsequent intratumoral 
injection of DOX loaded hydrogel (DOX-OS) in a xenograft mouse model of breast cancer 
resulted in greater and longer inhibition of tumor growth when compared to the DOX-treated 
control group. 
 
Hyaluronic acid: 
Hyaluronic acid (HA) is a biocompatible, biodegradable non-sulfated glycosaminoglycan 
which has been largely used over the years for drug delivery purposes.
[234]
 Injectable 
hyaluronic acid-based hydrogels can be formed using various methods, including Schiff-base 
reaction and covalent crosslinking with secondary agents.
[235]
 
 
For instance, an injectable 
hydrogel based on physical cross-linking of hyaluronic acid/adipic acid dihydrazide (HA-
ADH) and hyaluronic acid aldehyde (HA-CHO) was developed and subsequently loaded with 
two types of paclitaxel, namely microparticulate paxlitaxel (PTX) and 14 nm micelle form of 
PTX (Taxol).
[236]
 Consequently, in vitro PTX-gel showed slower release of paclitaxel 
compared to Taxol-gel as a result of smaller particle size of PTX. In addition, treatment of 
ovarian cancer in a xenograft mouse model with these hydrogels revealed significant 
reduction in tumor burden compared to control group, however no significant difference 
between tumor burden of mice treated with PTX-gel or Taxol-gel was observed, which was 
assumed to be a result of limited dissolution of PTX. Cho et al., developed a similar hydrogel 
and loaded them with platinum incorporated HA nanoparticles (PtNPs) and upon injection of 
this gel into the peritoneal cavity of ovarian cancer -bearing mice found that PtNP/gel and 
PtNP were not capable of inhibiting tumor growth and proliferation at later time points due to 
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pro-tumorigenic effect of HA in the DDS.
[53]
 In a different study, Ueda et al., designed an 
injectable hydrogel from interferon-alpha (IFN-α)-incorporated hyaluronic acid-tyramine 
(HA-Tyr) through oxidative coupling of Tyr with hydrogen peroxide (H2O2) and horseradish 
peroxide (HRP).
 [237, 238]
  The IFN-α-incorporated HA-Tyr gel was further combined with 
sorafenib (a small molecule tyrosine kinase inhibitor) for synergistic anti-cancer effect in a 
renal carcinoma xenograft mouse model. It was found that IFN-α-incorporated HA-Tyr 
gel+sorafenib caused the highest inhibition of tumor growth, which was further confirmed by 
the ratio of apoptotic cells and Ki-67-positive cells in the treated tumors. This synergistic 
effect was attributed to induction of apoptosis in conjugation with suppression of 
angiogenesis by IFN-α-incoporated HA-Tyr gel+sorafenib hydrogel. 
  
Alginate: 
Alginate a naturally occurring anionic polysaccharide has been extensively studied in tissue 
engineering and drug delivery avenues on account of its ideal biocompatibility and adjustable 
gelation properties.
[239, 240]
 Alginate-based injectable hydrogels can be made by exploiting a 
variety of chemistries including non-covalent bonding such as ionic bonds, schiff-base 
interactions and acylhydrazone Bonds.
[240]
 Ionic cross-linking of alginate chains with divalent 
cations such as Ca
2+
 provides a facile route to development of injectable formulations of this 
polymer. For instance most recently, Wang et al., developed an injectable alginate-calcium 
hydrogel with immobilized acetylated G5-NH2 PAMAM dendrimer-encapsulated platinum 
nanoparticles (DAcEPts) in its matrix for non-invasive photothermal ablation of tumors.
[51]
  
This hydrogel was capable of being degraded on-demand upon addition of a chelator 
(diethylene triamine pentacetic acid-DTPA). Intratumoral injection of DAcEPts containing 
hydrogel (H/DAcEPts) in lung cancer -bearing immunocompromised mice followed by NIR 
irradiation led to significant decrease in tumor volume compared to controls after 30 days of 
treatment. Interestingly, in the DAcEPts treated group, tumor-site temperature did not stay 
stable due to leakage of these nanoparticles out of the tumor tissue, however, the H/DAcEPts 
treated group showed maintenance of  temperature at 47 °C after each NIR irradiation. 
Additionally, after two intratumoral injections of the DTPA chelator (at day 9 and day 12) the 
liberated DAcEPts nanoparticles leached form the tumor tissue, which in turn resulted in an 
attenuated efficiency of the hydrogel in terms of tumor growth suppression.  
 
 
 
  
31 
 
Poly(organophosphazene): 
Poly(organophosphazene) is an inorganic/organic hybrid polymer that has immense potential 
for biomedical applications as a result of its hydrolytic degradability and non-toxic 
degradation products.
[241, 242]
 Furthermore, this hydrogel undergoes a sol-gel transition in 
psychological temperature that makes it a suitable candidate for anti-cancer injectable DDSs.   
For example, Al-Abd et al., loaded the poly(organophosphazene) thermogel with DOX for 
local delivery of this drug to human gastric tumor xenografts in mice.
[243] 
Interestingly, it was 
observed that DOX loaded gel (POL) had 40% and 90% sustained drug release over 5 weeks 
in vitro and in vivo, respectively. In vivo results suggested that POL had similar efficacy in 
suppressing tumor growth as DOX loaded solution (SOL), however POL showed dramatically 
decreased systemic toxicity compared to SOL leading to higher survival rates of animals after 
28 days of treatment. In a different study, Zhang et al., synthesized  poly(organophosphazene) 
nanocapsules loaded with superparamagnetic iron-oxide nanoparticle that transformed to a 
hydrogel (SPION-NHs) upon exposure to body temperature and it was further used for 
magnetic hyperthermia (MHT) and long-term magnetic resonance imaging (MRI).
[48]
 
Intratumoral injection of SPION-NHs in human brain cancer tumor xenograft in mice showed 
higher retention of SPION nanoparticles in the tumor tissue compared with that in the group 
treated with PEGylated SPIONs solution. Moreover, it was shown that treatment cycles of 
multiple MHT using SPION-NHs has a direct effect on tumor regression as mice treated with 
one or two cycles of MHT demonstrated resumed tumor growth after 5 days of treatment, 
however, mice treated with four cycles of MHT showed significant tumor eradication. Finally, 
long-term MRI monitoring of tumors injected with SPION-NHs showed dissipation of 
SPIONs from the tumor site as a result of apoptosis of tumor cells. Similarly, the same group 
loaded the SPION-NHs hydrogel with tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) (T/S-NHs) to synergistically abrogate tumors by multiple MHT and anti-cancer 
potential of TRAIL.
[244]
 Accordingly, it was shown that chemical structure of 
poly(organophosphazene) (PPZ) had a direct effect on in vitro degradation and subsequent 
release of TRAIL and SPIONs from the hydrogel, as nonionic side group on PPZ (indicated 
as T/S-NHs-1) led to fastest degradation rate as well as fastest SPIONs and TRAIL release, 
while, hydrogel made from PPZ with ionic side groups (indicated as T/S-NHs-2 and T/S-
NHs-3) showed much slower degradation rate and consequently slower TRAIL and SPIONs 
release. Additionally, intratumoral injection of T/S-NHs in a glioblastoma tumor xenograft in 
mice revealed that tumor growth was significantly inhibited in animals that received T/S-
NHs-2 with two cycles of MHT as a result of combinational therapy.  
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PLGA: 
PLGA, an FDA approved thermoplastic biopolymer, has also been deployed to generate 
injectable DDSs for cancer treatment because of its quick in-situ precipitation in aqueous 
environment. For instance, Chen et al., incorporated the iron(III) oxide (Fe3O4) nanoparticles 
into a PLGA solution for magnetic-hyperthermia regression of tumors.
[172]
 Intratumoral 
injection of this solution in a breast cancer xenograft mouse model  followed by only single 
magnetic ablation showed complete disappearance of the tumor after 3 days and without 
reoccurrence even after 1 month. The same group also developed another injectable DDS 
based on PLGA, which MoS2 nanosheets and DOX were incorporated into the implant for 
synergistic photothermal and chemotherapy of tumors (Figure 14).
 [171]
  Therefore, this 
implant showed controlled release of DOX in pH- and NIR- responsive manner. Furthermore, 
intratumoral injection of this composite in a breast cancer tumor xenograft mouse model 
followed by only one time NIR irradiation (5 min) led to disappearance of tumor after 7 days 
and no tumor recurrence was observed within 2 months from the treatment. Lastly, mice 
treated with PMD+NIR had 100 % of survival rate over a period of 50 days, which indicated 
high efficiency of this local synergistic treatment.  
         
 
3. Future trends 
 
In the following sections, we will briefly highlight some of the recent trends in anti-tumor 
polymeric implantable DDSs with special emphasis on emerging biopolymers as well as state-
of-the-art implantable anti-cancer micro-devices. Furthermore, a novel therapeutic modality, 
based on biopolymeric implantable DDSs for treatment of various cancers is highlighted.  
 
3.1 Emerging biopolymers 
 
Recent advances in biopolymers have brought about new generations of biopolymers with 
peculiar characteristics such as self-healing,
[223, 245-247]
 photoluminescence,
[175]
 and thermo-
degradability,
[248, 249]
 that have greatly contributed to development of novel multi-functional 
anti-cancer DDSs.  
 
 
 
  
33 
 
Self-healing   
 
Stability of implants after implantation is of great importance particularly considering its 
direct effect on corresponding drug release profile. Hence, DDSs that can autonomously heal 
themselves upon damage and restore the integrity and functionality of DDS have recently 
gained much attention.
[223, 245-247] 
Worth noting that self-healing implantable DDSs are often 
made from hydrogels based on either dynamic covalent bonds or non-covalent bonds, which 
allow reversible formation of hydrogel network.
[250]
 For example, Wang et al., developed an 
injectable self-healing hydrogel from a mixture of glycol chitosan, telechelic difunctional poly 
(ethylene glycol) (DF-PEG) and saline ions that were used for microwave tumor ablation.
[245]
 
Periodic step-strain experiment (2 cycles of 1% then 300% strain) showed that the hydrogel 
was capable of recovering 100% of storage modulus almost instantly. The intrinsic self-
healing capability of this hydrogel stemmed from Schiff base bond between amino groups of 
chitosan and benzaldehyde groups of DF-PEG. In vivo biocompatibility study demonstrated 
only a mild foreign-body reaction indicating good biocompatibility. Intratumoral injection of 
DOX loaded hydrogel in glioma tumor xenograft (in mice), in combination with microwave 
treatment led to effective suppression of tumor growth within 14 days that was further 
confirmed with histological assessment of tumors ex vivo. Similarly, Yang et al., used the 
same hydrogel in combination with PTX and intratumoral injection of this DDS in liver 
cancer tumor xenograft (in mice) showed significant inhibition of tumor growth when 
compared to that in mice that received Pluronic F127 hydrogel loaded with PTX.
[246] 
This 
observation was assumed to be the result of unique self-healing ability of the hydrogel 
allowing it to rebuild as a whole after injection which prevented the leak of PTX and 
subsequently resulted in longer-term anti-tumor efficacy.  
In a recent effort, Xing et al., made a self-healing, shear-thinning hydrogel based on 
electrostatic interactions between positively charged collagen chains and anionic cluster of 
[AuCl4] ions that subsequently formed gold nanoparticles (AuNPs) in the gel.
[223]
 Continuous 
step-strain test (3 cycles of 1% and then 500% strain) showed that the broken structure 
recovered rapidly and demonstrated normal hydrogel-like behavior. Intratumoral injection of 
hydrogel showed persistent retention in a breast  tumor xenograft (in mice) and subsequently 
displayed sustained release of model drug (Meso-Tetra (N -methyl-4-pyridyl) porphine 
tetrachloride/ TMPyP) within the tumor site. Intratumoral injection of the hydrogel followed 
by laser irradiation showed suppression of tumor proliferation depending on number of 
treatment cycles, as animals that received one cycle of irradiation showed initial tumor 
volume decline, followed by rapid tumor growth 5 days post treatment, whereas, animals that 
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received five cycles of irradiation showed delayed tumor growth and even tumor eradication 
after 23 days. lastly, Huebsch et al., fabricated a self-healing alginate hydrogel that was cross-
linked with calcium sulfate.
[247] 
The polysaccharide was cross-linked by divalent cations 
(Ca
2+
) and it was observed that ultrasound was capable of disrupting ionic cross-linking to 
accelerate mitoxantrone release, while Ca
2+
 ions in physiological fluids allowed cross-links to 
reform after removal of the ultrasound (Figure 15A). Interestingly, in vitro studies using 
MDA-MB-231 and MCF7 breast cancer cell lines revealed that ultrasound-mediated pulsatile 
release of mitoxantrone had significantly higher anti-tumor activity when compared with 
sustained release of drug from the same hydrogel. Injection of this hydrogel adjacent to 
MDA-MB-231 tumor xenografts in mice followed by ultrasound treatment of animal showed 
higher inhibition of tumor growth as well as higher survival rate when compared to those in 
mice treated with systemic exposure of drug or drug-loaded gel without ultrasound.   
Photoluminescence: 
Fate of polymeric DDSs after implantation is vital for patient’s compliance to therapy.
[251]
 
Hence, traditionally fluorescent dyes have been incorporated into DDSs to allow optical 
tracking of these systems, however, fluorescent dyes are potentially toxic and eventually leak 
out of the DDS.
[252]
 On the other hand, sericin based (a major component of natural silk) 
hydrogel was found to exhibit excellent photoluminescence as well as in vivo 
biocompatibility.
[253] 
Consequently, Liu et al., developed an injectable hydrogel, from a 
mixture of sericin functionalized with adipic acid dihydrazide (Sericin-ADH) and dextran 
dialdehyde (DEX-Al), for use as an optically trackable DDS for treatment of malignant 
melanoma (Figure 15B).
[175] 
The hydrogel was formed based on hydrazone bonds between 
amino groups of sericin-ADH and carbonyl groups of DEX-Al. Photoluminescence of 
hydrogels were observed under two excitation wave lengths of 405 and 488 nm. After 
subcutaneous injection of these gels into dorsal skin of mice, they were readily detected and 
visualized with excitation wavelength at 405 nm and emission wavelength at 530 nm. 
Moreover, it was shown that there was a direct correlation between degradation of the 
hydrogels and their corresponding fluorescence intensity. Ultimately, injection of DOX-
loaded gels in the vicinity of a melanoma tumor in mice led to increased tumor growth 
suppression and prolonged survival time once compared with the groups treated with free 
DOX.  
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Thermo degradation: 
Thermo-sensitive biopolymers have been extensively used in the field of drug delivery to 
fabricate DDSs that undergo sol-gel transition above their lower critical solution temperature 
(LCST).
[118, 254]
 However, recently a new generation of thermo-sensitive biopolymers were 
explored that can undergo degradation and/or chain dissociation after being exposed to 
heat.
[13]
 This feature can be further used to allow on demand delivery of therapeutic agents via 
administration of heat. For instance, Hu et al., designed a thermo-responsive injectable 
hydrogel by cross-linking four-arm amine-terminated poly(ethylene glycol) with an azo-
containing linker and the hydrogel showed rapid degradation above 44 °C due to breakage of 
azo bonds (Figure 15C).
[248]
 Embedding this hydrogel with photothermal nanoparticles 
(dendritic platinum-copper nanoparticles) enabled on-demand and dose-tunable release of 
entrapped DOX in vitro upon irradiation with NIR light. In vivo Injection of this hydrogel 
under the dorsal skin of nude mice followed by NIR irradiation (once per day for 10 min) 
degraded the majority of hydrogel mass after 3 days of treatment. Finally, intratumoral 
injection of DOX loaded gel into breast tumor xenografts (in mice) followed by NIR 
irradiation led to significant regression of tumor volume as a result of fast release of DOX in 
the tumor site. Wang et al., synthesized a different thermo-degradable injectable hydrogel 
composed of PEG-modified PAMAM dendrimer encapsulated with platinum nanoparticles 
(DEPt-PEG) and alpha-cyclodextrin (α-CD).
[249]
 The linear PEG chains threaded into a series 
of CD cavities via a well know host-guest interaction, to form pseudopolyrotaxane (PPR) 
assemblies and subsequently strong hydrogen bonding among the adjacent threaded CDs 
promoted physical gel formation. Interestingly, the threading-dethreading transition is a 
thermosensitive phenomenon that facilitated on-demand degradation of the hydrogel. The 
DEPt-PEG/α-CD hydrogel showed a temperature increase up to 46 °C only after 5 min of 
NIR irradiation, and was observed that hydrogel degradation had a direct correlation with 
duration of NIR irradiation. In vitro, bortezomib loaded hydrogels were capable of markedly 
abrogating human lung cancer cells after NIR irradiation and further, subcutaneous injection 
of fluorescent dye (cyanine 5.5)-loaded hydrogel in mice exhibited much higher dye release 
after NIR radiation, which suggested that thermo-degradation of this hydrogel can be used for 
on-demand delivery of drugs.   
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3.2 Anti-cancer polymeric micro-devices 
 
Recent efforts to institute miniaturized drug delivery devices has ultimately led to 
development of integrated systems that incorporated device technology with therapeutic 
molecules to create implantable devices capable of disease treatment in situ.
[255-257]
 Based on 
the design of these micro-devices they could present different options such as allowing 
continuous or intermittent delivery, operating for short or long periods.
[255] 
Similar to 
traditional DDSs, these devices can either exert passive delivery of a drug or they can permit 
real-time control of drug dosage by means of external stimulus.
[258]
 In the following section, 
some of the most salient examples of polymeric micro-devices for cancer therapy are 
reviewed.  
Jonas et al., recently engineered a small cylindrical device (via micro-machining from a 
medical grade acetyl resin blocks) designed to release a wide range of anti-cancer drugs from 
16 discrete reservoirs on its perimeter (Figure 16A).
[259]
 The device was directly implanted 
into tumors of different types using a biopsy procedure and left in there for 24 h for quick, 
parallel investigation of drug sensitivity in in vivo tumors. Next, the device and a small region 
of tissue were removed using a coring biopsy needle, to determine the anti-neoplastic effect of 
each treatment. In order to modify the release rate of each drug in the reservoir, three different 
techniques were used: (1) altering the size of reservoir opening, (2) embedding drugs into 
polymeric matrix (PEG) and (3) using a hydrophilic expansive polymer that would expand 
upon contact with fluid in the tumor in order to deliver hydrophobic drugs. Consequently, It 
was shown that the device was capable of delivering individual or combination (co-delivered 
from one reservoir or delivered separately from two adjacent reservoirs) of drugs into 
confined regions of tumor tissue. The authors further evaluated the pharmacokinetics of DOX 
release from the device in human breast carcinoma tumor xenografts and it was shown that 
the drug released from device can diffuse 200 to 300 µm into tumor tissue. In addition, this 
device was found to be useful in combatting tumor heterogeneity (a major challenge in all 
diagnostics) by implanting a device, with sixteen identically loaded reservoirs (with DOX) on 
different locations of the device, in the non-necrotic periphery of skin cancer tumor 
xenografts.         
Dosage of drug and frequency of its administration play a crucial role in the treatment of 
chronic diseases such cancer.
[260, 261]
 Consequently, advanced techniques that allow on 
demand, precise and controlled local delivery of drugs are highly needed for individualized 
disease treatment.
[262]
 Owing to digital capabilities of microelectromechanical systems 
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(MEMS) they allow for complex temporal profiles, while the manufacturing techniques used 
in microelectronic industry can lead to greater device uniformity and reproducibility than 
currently available to pharmaceutical and biomedical industries.
[263-266]
 On account of such 
desirable features MEMS devices have been recently explored for anti-cancer drug delivery 
purposes and have shown some promising results.
[265, 267, 268]
. However, the major issues with 
MEMS devices are related to biocompatibility of materials used to institute the device as well 
as constant need for a sustained power supply. Consequently, in a notable effort Chin et al., 
used photolithography to develop a biocompatible and biodegradable MEMS micro-device 
from PEG diacrylate (PEGDA), which contained moving parts that can be controlled by an 
external magnet (Figure 16B).
[268]
 Specifically, two different designs of this device, single-
gear and geneva drive, were tested in vivo on a mouse model. Single-gear device contained a 
multi-reservoir gear, where one of them was loaded with iron oxide nanoparticles (NPs) and 
the others with drugs. On the other hand, geneva drive had two engaged gears, a driving gear 
that was doped with iron oxide NPs and a driven gear with six drug loaded reservoirs. The 
concept of release for both designs were the same, where movement of an external magnet 
caused motion in the gears (owing to presence of NPs) and the drug in each reservoir was 
released once the aperture on top it aligned with another aperture on topmost layer of the 
assembled device. Subcutaneous implantation of the geneva drive device (in a mouse model) 
loaded with two different fluorescent dyes showed successful movement of gears in vivo 
which led to controlled release of the dyes. Furthermore, the DOX-loaded single gear device 
(loaded with 10% of a single standard chemotherapy dose) was implanted adjacent to a 
human osteosarcoma xenograft (in a mouse model), which was actuated once every 2 days, 
over a period of 10 days. Consequently, this showed the greatest tumor volume reductions 
with the presence of tumor necrosis, and also caused the lowest levels of cardiotoxicity 
compared to all other treatment groups (including systemic administration of various 
concentrations of DOX with different frequencies). Lastly, analysis of the excised device and 
surrounding tissue showed no signs of chronic inflammation and revealed normal wound 
healing indicating good biocompatibility of this device.  
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3.3 Emerging therapeutic modality based on biopolymeric implantable DDSs  
 
Considering the versatility of implantable biopolymeric DDSs, it allows them to be loaded 
with novel anti-cancer therapeutic agents to deliver high concentrations to the disease site. 
Therefore, in this section we will briefly discuss a recently emerging therapeutic modality to 
abrogate primary tumors and subsequently bring examples of implantable biopolymer-based 
DDSs that were used to deliver these agents directly to the tumor.  
 
 
Cancer immunotherapy 
Cancer immunotherapy involves any intervention that aids the immune system to eradicate a 
malignancy.
[269]
 Immunotherapy modalities can function via two different mechanisms, either 
by stimulation of the intrinsic immune system or by unleashing extrinsic immune system 
components such as specific proteins to be recognized and targeted by immune cells.
[9]
 
However, multiple factors have hampered the success of these therapies in clinical cases 
including; associated toxicity, difficulties involved with defining the optimal dosage and 
schedule of immunotherapy and at last lack of efficiency in patients with a large tumor burden. 
[9, 270, 271]  
Biomaterial based systems, however, are capable of addressing these issues owing to 
their intriguing properties such as protecting the bioactive agents or cells, exerting control 
over their spatiotemporal release and competency to deliver more than one agent from a 
single platform.
[272]
 Consequently, a wide range of biomaterials have been used for delivery of 
immunomodulatory factors and here we will only highlight the most recently developed 
implantable bio-polymeric DDSs used for this purpose. In the context of cancer 
immunotherapy these implantable DDSs can be used in two well distinguished ways, either 
for delivering immunomodulatory agents that override checkpoints in the cancer-immunity 
cycle or to deliver cells for adoptive cell transfer (ACT) into cancerous tissue to enhance their 
survival and proliferation.
[273]
  
 
Delivery of immunomodulatory factors 
Many types of immunomodulatory agents, antibodies, antigens, adjuvants, cytokines and 
checkpoint inhibitors have been loaded into implantable bio-polymeric DDSs to provide 
immune-protection against cancer.
[274]
 For example, Bencherif and his colleagues developed a 
methacrylated alginate (MA-alginate) sponge-like cryogel containing covalently conjugated 
RGD peptide which was encapsulated with GM-CSF (granulocyte-macrophage colony-
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stimulating factor), CpG ODN (cytosine-phosphodiester guanine oligodeoxynucleotide) and 
irradiated tumor cells (B16-F10 mouse skin melanoma cells).
[275] 
Subcutaneous injection of 
this cryogel vaccine into a mouse model brought about a durable and specific anti-tumor T-
cell response which led to 80% survival rate in a B16-F10 tumor model. Moreover, it was 
shown that cryogel vaccines bestow long lasting protective immunity as 100% of vaccinated 
mice that survived the initial tumor challenge survived the subsequent second challenge.    
          
Delivery of cells for ACT 
ACT offers great advantages over other methods of cancer immunotherapies, which heavily 
rely on in vivo recruitment of a sufficient number of antitumor T cells with required functions 
to instigate cancer regression.
[276]
 Usually in ACT a large pool of antitumor lymphocyte, 
capable of recognizing tumor cells, are grown and proliferated in vitro and subsequently 
administered to the patient with the aim of providing a tumor microenvironment that supports 
antitumor immunity.
[277] 
Nevertheless, recent years have witnessed emergence of bio-
polymeric scaffolds as platforms for improving function of these adoptive cells and enabling 
their local delivery to the tumor site. 
[269, 278]
 For example, Stephan et al., developed a 
bioactive polymeric carrier designed for expanding and delivering tumor-reactive T cells for 
treating inoperable or incompletely removed tumors in a mouse breast cancer resection model 
(Figure 17).
[65]
 The microporous scaffolds were made of alginate functionalized with 
collagen-mimetic peptide (used to facilitate migration of T cells through the scaffolds by 
means of α2β1 collagen receptor) using ionic crosslinking. Furthermore, porous silica 
microparticles containing anti-CD3, anti-CD28 and anti-CD137 antibodies were incorporated 
into the scaffold to create stimulatory microenvironment for cytotoxic T-lymphocytes (CTL) 
proliferation. For in vivo studies breast cancer xenografts in  mice were intentionally partially 
resected to mimic reoccurrence post-resection. Ultimately, implantation of these scaffolds at 
the resection site led to higher T cell proliferation and consequently none of the treated mice 
showed tumor reoccurrence after a period of 80 days, in contradiction to the control group 
which all died due to cancer relapse. In another study Aliperta and his colleagues reported a 
macroporous cryogel scaffold made from four-arm poly(ethylene glycol)-heparin that were 
used for housing gene-modified human mesenchymal  stromal cells (MSCs), capable of 
secreting anti-CD33-anti-CD3 bispecific antibody (bsAb), for treatment of acute myeloid 
leukemia (AML).
[279]
 This scaffold supported the proliferation and survival of bsAb-releasing-
MSCs and was observed to secret bsAb in a sustained manner both in vitro and in vivo. For 
purpose of in vivo anti-tumor evaluation, leukemia tumor cells (CD33
+
 MOLM-13 cells) were 
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injected into right leg of mice and the scaffolds were subcutaneously implanted into the left 
leg. Consequently, it was shown that sufficient amount of released bsAb reached circulation 
leading to efficient redirection of T cells to CD33 positive AML cells and causing significant 
reduction in tumor size.               
 
                       
4. Conclusion 
 
Despite a steady decrease in cancer mortality over the last few decades, the current standards 
of care in cancer treatment encounter major obstacles in efficiently treating the disease. 
Therefore, bio-polymeric implantable DDSs have been designed to overcome hurdles faced 
by conventional therapies, by means of local delivery of therapeutic agents directly to the 
tumor site. These DDDs have consequently  shown immense promise in treating malignant 
tumors (or preventing disease  recurrence) in animal models as well as in some clinical cases. 
Not only do these DDSs possess intriguing properties (such as biocompatibility, 
biodegradability and trackability) but they are also capable of delivering a variety of anti-
cancer therapeutic agents while exerting precise spatiotemporal control over their release. 
More importantly, in multiple cases these DDSs were shown to be useful for combinational 
therapy of tumors, using chemotherapeutic drugs in conjugation with either hyperthermia or 
photodynamic therapy or gene therapy. Nevertheless, in order for bio-polymeric implantable 
DDSs to reach a broad clinical implementation, scientists have to discover simple polymer 
chemistries that are easy to follow while offering sufficient safety. Lastly, continual 
communication between scientists and clinicians is crucial for establishing new treatment 
standards, based on the cancer type and stage, which would lead to optimal therapeutic and 
patient outcomes.   
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Figure captions: 
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Figure 1. Schematic of systemic drug delivery versus local drug delivery for treatment of 
malignant tumors, including various types of bio-polymeric implantable systems used for 
local drug delivery and different anti-cancer therapeutic modalities employed based on these 
implantable systems.  
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Figure 2. Schematic showing different mechanisms of drug release from bio-polymeric 
implantable drug delivery systems (DDSs). 
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Figure 3. Preparation and in vivo anti-tumor performance of DOX loaded films. A) Strategies 
to generate doxorubicin-loaded films that are water-insoluble with variable β-sheet content. 
B) Free-standing doxorubicin-loaded silk films in the dry state. C) Weight of primary tumours 
at the end of the study (week 6). D)  In vivo tumor cell-specific bioluminescence of 
representative mice from each treatment group at week 6. Plot symbols are defined in panel 
(C). E) Metastatic spread of cancer cells to organs at week 6. Plot symbols are defined in 
panel (C), Reprinted from [21], Copyright (2012), with permission from Elsevier. 
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Figure 4. Dextran-based hydrogel scaffold as prophylactic agent for in vivo local gene/drug 
delivery combined with phototherapy, before and after tumor resection in mice model of 
colorectal cancer. A) Development of smart hydrogel-nanoparticle patch and subsequent 
implantation in mice model. B) Tumor burden following treatment as measured by luciferase 
activity, without tumor resection, C) and after tumor resection. D) Survival plot analysis of 
mice treated with hydrogel scaffolds for single therapies or triple therapy. Reprinted by 
permission from Macmillan Publishers Ltd: Nature Materials 
[67]
, Copyright (2016). 
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Figure 5. Design, characterization and in vivo anti-tumor performance of implantable 
paclitaxel eluting device (PED). A) Schematic of localized therapeutic approach with PED. B) 
Macroscopic visualizations of the local delivery device. C) Scanning electron microscopy 
images of PLGA coating on top of steel (“C” = coating and “S” = steel). D) Relative tumor 
growth curves of PDAC-3 mouse xenografts after treatment with either paclitaxel intravenous 
or PED treatment. E) Survival plot showing longer median overall survival (28 day increase) 
for mice treated with PED compared to mice treated with I.V. injection of paclitaxel. F) 
Histological analysis of PDAC-3 tumors after treatment with PED showing higher areas of 
necrosis (N) compared to preserved tumor structure (T) in group treated with I.V. paclitaxel. 
Reprinted from [28], Copyright (2016), with permission from Elsevier.  
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Figure 6. pNIPAAm-based hybrid hydrogel for preventing post-operative recurrence of breast 
cancer. A) Design of hybrid hydrogel and mechanism of operation of resulting DDS by dual 
DOX release and photothermal therapy (PTT). B) In vitro release profile of DOX from the 
DDS in PBS. C) In vivo locoregional tumor recurrence. Reprinted by permission from 
Macmillan Publishers Ltd: NPG Asia Materials 
[119]
, Copyright (2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Drug loaded asymmetric multilayer PLA nanofibers (AMPN) for preventing liver 
cancer recurrence. A)  Graphical presentation of multilayer nanofibers and scanning electron 
microscopy image of five layered (M5) nanofibrous mat. The top layer (i) in M5 and M3 mats 
contained PLA films to allow one sided release of drugs. B) Schematic illustration of 
performance of drug-loaded AMPN mats in human body for prevention of tumor recurrence 
after HCC surgery. C) Tumor recurrence rate, D) average tumor volume, and E) survival time 
as a function of time, for treated animals, post “subcutaneous tumor” surgery. Reprinted from 
[39]
, Copyright (2015), with permission from Elsevier.  
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Figure 8. A nanofibrous PCL-based composite for synergistic chemo- and photothermal 
tumor therapy. A) Schematic showing preparation of composite fibers as well as their 
subsequent implantation procedure for dual therapy of tumors. B) Tumor volume as a 
function of time after different treatments. C) Images of mice with tumors and photograph of 
corresponding excised tumors after 11 days of treatments. D) Mean tumor weights after 11 
days of treatments. Reproduced from 
[151]
 with permission of The Royal Society of Chemistry. 
 
 
 
 
 
 
 
  
59 
 
 
 
Figure 9. Core-shell micelle-loaded nanofibers for efficient cancer therapy. A) Schematic 
representation of multi-axial fibers and their corresponding in vivo performance. B) 
Biodistribution (for different time points) in different organs of mice after receiving different 
treatments. C) Tumor volume and D) survival rate of treated tumor-bearing mice as a function 
of time. Reprinted with permission from 
[139]
, Copyright (2015) American Chemical Society. 
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Figure 10. 3D printed patch for local delivery of 5-FU for pancreatic growth suspension. A) 
Schematic showing sample preparation procedure. B) Schematic and photograph of printed 
patches with different geometries. C) Relative tumor size as a function of time in mice after 
implantation of drug loaded patches. D) Photographs of excised tumors and the patches 4 
weeks after implantation. Reprinted from [26], Copyright (2016), with permission from 
Elsevier. 
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Figure 11. Injectable thermosensitive nanoparticle-assembled hydrogel for peritumoral 
chemotherapy. A) Schematic showing design concept and in vivo mechanism of action of the 
hydrogels. B) Images of sol-gel transition of hydrogels at 37 °C. C) Tumor volume change 
and D) percentage of survival, as a function of time, for treated animals. Reprinted with 
permission from [40], Copyright (2016) American Chemical Society. 
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Figure 12. Injectable polydopamine nanoparticle-knotted PEG hydrogel for on demand 
chemo-photothermal therapy of tumors. A) Schematics showing preparation PDA/PEG 
hydrogel and subsequent SN38 release mechanism from the hydrogel upon NIR irradiation. 
B) Tumor volume change plot for different treated groups. C) Photograph of excised tumors 
and D) their corresponding average weight. Reprinted with permission from 
[177]
, Copyright 
(2017) American Chemical Society.  
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Figure 13. Collagen-based injectable hybrid hydrogel for synergistic photothermal therapy 
(PTT) and photodynamic therapy (PDT) of breast cancer tumor in mice model. A) Schematic 
representation of injectable hybrid hydrogel, containing gold nanoparticles (Au NPs) and 
photosensitizer (PS), and its corresponding in vivo anti-tumor mechanism. B) Tumor growth 
graphs of mice treated with different treatments. C) Tumor recurrence in different groups. 
Reprinted from [53], Copyright (2017), with permission from Elsevier. 
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Figure 14. Multifunctional PLGA/MoS2/DOX (PMD) oleosol as injectable implant for 
synergistic chemo- and hyperthermia tumor therapy. A) Schematic illustration showing in 
vitro phase transformation of oleosol, oleosol microstructure, and in vivo dual mechanism of 
tumor therapy triggered by NIR irradiation. B) In vivo thermal images of PMD implanted 
mice after continuous NIR irradiation for different durations. C) Tumor volume change in 
mice with different treatments. D) Survival rate of mice following various treatments. 
Reprinted from 
[171]
, Copyright (2015), with permission from Wiley-VCH.  
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Figure 15. Peculiar characteristics of emerging biopolymers including self-healing, 
photoluminescence and thermo degradation. A) Ultrasound-trigerred disruption of ionically 
crosslinked alginate hydrogels and their subsequent self-healing in physiological fluids. 
Reprinted from 
[247]
, Copyright (2014), with permission from National Academy of Sciences. 
B) Schematic showing preparation of sericin-based hydrogels and their subsequent in vivo 
photoluminescence after implantation. Reprinted from 
[175]
, Copyright (2016), with 
permission from American Chemical Society. C) Schematic illustration of thermal 
degradation in hydrogels prepared from cross-linking of 4-arm-PEG-NH2 via thermo-
degradable linkers (TDL). Reprinted from 
[248]
, Copyright (2017), with permission from 
Elsevier. 
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Figure 16. Anti-cancer polymeric micro-devices. A) Schematic Illustrations showing 
implantation of cylindrical device into the tumor tissue and post processing of the excised 
tumor section, and, B) Showing three methods used for precise release rate of drugs from each 
reservoir. From 
[259]
, Reprinted with permission from AAAS. C) Schematic representations of 
geneva drive and single gear implantable MEMS devices made entirely from biocompatible 
PEGDA, and, D) In vivo movement and controlled release of dye from the Geneva drive 
device. From 
[268]
, Reprinted with permission from AAAS.  
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Figure 17. Alginate-based scaffold for delivery of tumor-reactive T cells for treating 
inoperable or incompletely removed tumors. A) Schematic showing local delivery of T cells 
to the tumor using the biopolymeric scaffold. B) Bioluminescence imaging of tumors after 
different treatments. C) Survival curves for mice applied to different treatments. Reprinted by 
permission from Macmillan Publishers Ltd: Nature Biotechnology 
[65]
, Copyright (2015). 
 
